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Abstract
The 2015 EU R&D Scoreboard reports economic and financial information on the world’s top 2500 companies that invested 
€607.2 billion in R&D over the last fiscal year (2014).  It comprises 608 companies based in the EU, 829 companies based in 
the US, 360 in Japan and 703 from the rest of the world. 
Key findings from the 2015 Scoreboard:
- In 2014, the top world 2500 R&D Scoreboard companies raised their R&D by 6.8%, while revenues continued to grow at a 
significant lower pace (2.2%). 
- Companies based in the EU showed an annual R&D investment growth rate of 3.3%, slightly improving the previous year’s 
performance (2.5%). Companies based in the US showed a stronger R&D investment growth rate (8.1%). The Chinese companies, 
3rd largest country by number of companies in this edition, increased R&D investments by 23.6%.  
- Companies in the ICT, Pharmaceuticals and Automobiles sectors continue to dominate the top 10 places in the world ranking. 
As in the previous edition, the top R&D investors are Volkswagen, Samsung, Microsoft, Intel and Novartis. The most significant 
changes at the top of the ranking in 2014 are the climb of Google to 6th place (from 9th), and of Pfizer to the 10th place (from 
15th). Huawei (15th) and Apple (18th) accelerated in 2014 their race to the top, jumping 11 and 17 positions respectively. 
- An analysis of the patent portfolios of the world’s top R&D investors shows that EU and US companies have the highest 
degrees of internationalisation of their inventive activities: 26% and 22% of their patent families are developed by inventors 
located outside the region. While the US appear to be the preferred location for health related inventions (pharma and biotech 
in particular), Europe is the most attractive place for the inventive activities of automobile companies.
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The “EU Industrial R&D Investment Scoreboard” (the 
Scoreboard), published annually since 2004, monitors top 
EU based R&D investing companies benchmarking them 
with top investors located in other parts of the world. The 
Scoreboard is part of the European Commission’s monitoring 
activities to improve the understanding of trends in R&D 
investment by the business sector. In the context of the EU 
agenda for Jobs, Growth and Investment, the contribution 
Summary
Highlights 
• In 2014, the top world 2500 R&D Scoreboard companies raised their Research and Development investments by 6.8%, 
while net sales continued to grow at a significant lower pace (2.2%). The positive evolution of R&D investments confirms 
the crucial strategic role that knowledge generation plays for these companies in a context of global competition and 
increasingly accelerated technical change.
• Companies based in the EU showed an annual R&D investment growth rate of 3.3%, slightly improving the previous 
year’s performance (2.5%). This reflects the mixed performance of medium- and high-tech sectors, e.g. good results 
by companies such as VW (11.7%), Ericsson (17.3%), AstraZeneca (21.4%), Bayer (13.2%), Total (42.6%) and Bosch 
(8.4%) have been offset by those of companies such as Nokia (-21.4%), Alstom (-29.5%), STMicroelectronics (-31.6%), 
GlaxoSmithKline (-10.5%), Royal Bank of Scotland (-31.5%) and Finmeccanica (-14.6%).
• Companies based in the US showed a stronger R&D investment growth rate (8.1%), driven by the good performance of its 
R&D-intensive ICT and health companies, which represent more than two thirds of US total R&D investment. 
• The Chinese companies, from the 3rd largest country by number of companies in this edition, increased R&D investments 
by 23.6%, mostly due to the outstanding results shown in IT-hardware and software sectors. These same ICT sectors 
largely explained the strong R&D investment performance of companies based in Taiwan (12.4%) and South Korea 
(10.6%).  
• An analysis of the health (biopharma and health equipment sectors) and ICT sectors shows a significant gap for the EU 
vis-à-vis the US in terms of R&D investment. However, the Scoreboard also shows there are a number of world-beating 
EU companies of substantial size in these sectors, e.g. Novo Nordisk, ASML and ARM. The gap is due to the fact that there 
are too few of them. Further investigation on an enlarged sample of top EU-1000 companies showed that there are a 
significant number of high-performance companies with the potential to further climb-up in the ranking of world top R&D 
investors (e.g. Dialog Semiconductor, Gameloft, Generix, Playtech and Wirecard).
• Companies in the ICT, Pharmaceuticals and Automobiles sectors continue to dominate the top 10 places in the world 
ranking. As in the previous edition, the top R&D investors are Volkswagen, Samsung, Microsoft, Intel and Novartis. The 
most significant changes at the top of the ranking in 2014 are the climb of Google to 6th place (from 9th), and of Pfizer to 
the 10th  place (from 15th ). Huawei (15th) and Apple (18th) accelerated in 2014 their race to the top, jumping 11 and 17 
positions respectively. The slip down in the ranking of the EU based companies present in the top 50 is in part due to the 
depreciation of the euro which started in the second half of 2014. 
• An analysis of the patent portfolios of the world’s top R&D investors shows that EU and US based companies have the 
highest degrees of internationalisation of their inventive activities: 26% and 22% of their patent families are developed 
by inventors located outside the region. While the US appear to be the preferred location for health related inventions 
(pharma and biotech in particular), Europe is the most attractive place for the inventive activities of automobile companies.
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of the business sector to reach the 3% objective for R&D 
intensity in the European economy is crucial. Evidence shows 
that most of the EU R&D gap with respect to main world 
competitors comes from an insufficient number of leading 
innovative companies in key high-tech sectors. 
The Scoreboard relies on economic and financial information 
on the World’s top 2500 companies that invested €607.2 
billion in R&D –representing about 90% of the total 
expenditure on R&D by business worldwide. The data is 
collected from the latest available companies’ accounts 
(i.e. for this year’s edition usually the fiscal year 2014/151). 
It complements official territorial statistics (such as BERD) 
in the study of important questions related to companies’ 
innovation behaviour in a global context. It is a reliable, 
up-to-date benchmarking tool for comparisons between 
companies, sectors, and geographical areas, as well as 
to monitor and analyse emerging investment trends and 
patterns. 
The 2015 Scoreboard sample contains 608 companies based 
in the EU, 829 companies based in the US, 360 in Japan and 
703 from the rest of the world. 
1 The latest available annual account is taken into account for each individual company. 
Due to differences in accounting practices, however, these refer to a range of dates 
from 2013 to the first half year of 2015 (see  the  methodological notes in the Annex).
In 2014, the top world R&D investors increased their 
Research and Development investments by 6.8% to 
reach a figure of €607.2bn while net sales continued 
to grow at a significant lower pace (2.2%). This 
reaffirms the continuity of the robust growth trend 
of R&D investments observed since 2010 (see Figure 
S.1). 
This positive evolution of R&D investments by the top world 
investors confirms the crucial strategic role that knowledge 
generation plays for these companies in a context of global 
competition and increasingly accelerated technological 
change. Capital expenditures continue to grow at a 
significantly lower rate (0.9%), although such investments 
still remain an important factor for many firm’s productivity 
enhancement (companies in the sample devote in average 
7% of their sales to capital investments, compared to  the 
3.4% devoted to R&D). However, capital investment is 
usually far less important for companies in R&D-intensive 
sectors such as biopharma and software.  The number of 
employees for the world sample has increased by 1.5%, an 
improvement with respect to last year’s stagnation (-0.1%). 
Figure S1 below shows the longer-term R&D trends for a 
subset of companies with available data for the past eight 
years.
Figure S.1 - One-year growth rate of R&D investment and net sales.
Note:   Figures for the three variables have been computed on 1832 out of the 2500 companies for which data are available for the entire period 
2007-2014
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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In 2014, the 608 EU companies among the top world 
2500 R&D investors increased R&D by 3.3%, slightly 
improving the previous year’s performance (2.5%) in 
a context of sales stagnation (-1.0%) and return to 
positive profits (5.0%, compared to -6.6% in 2013).
Companies based in the US showed the strongest R&D 
growth rate (8.1%, well above the growth of sales 3.6%, and 
despite a fall in profits of -0.8%), while Japanese companies 
increased R&D by 2.6%, despite a significant growth of net 
sales (4.3%) and profits (8.2%). The Scoreboard sample 
shows an increasing number of Chinese companies, now 
fourth group in terms of number of companies and total 
R&D investment. The Chinese companies increased R&D by 
23.6% in 2014.   
Figure S.2 shows the R&D and sales trends over the period 
2009-2014 for a subset of companies based in the EU, US, 
Japan and China2. These four regions account for 86.5% of 
the total R&D investment made by the 2500 Scoreboard 
sample: EU 28.1%, US 38.2%, Japan 14.3% and China 5.9%.
2 Companies for which data are available for the whole 2009-2014 period. 
Trends over the past 6 years show a hesitant recovery 
of companies based in the EU, especially in terms of 
net sales whereas their the US counterparts seem to 
have returned to the high R&D investment levels that 
obtained prior to the crisis.  
Japanese companies, hardly affected by the crisis, show 
positive results in terms of R&D and net sales over the last 
two years, indicating continuing recovery after the earthquake 
of 2011. R&D investment by the Chinese companies rose 
significantly over the period 2008-2010 and remained at 
high levels in recent years. On the contrary, their net sales 
slowed down during the crisis, picked up again and then 
decelerated again in the past three years. However, please 
note that this refer only to 145 Chinese companies for which 
data were available over the 2009-2014 period compared to 
the 301 firms listed in this year’s Scoreboard.
Figure S.2 - One-year growth rate of R&D investment and net sales, by main world region.
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Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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In 2014, employment has increased for Scoreboard 
companies based in the EU (1.8%), US (1.4%), which 
represents an improvement with respect to the situation in 
2013 (when the number of employees decreased by 3.1% in 
US based companies and by 0.6% in European ones). For the 
period 2006-2014, the employment increase observed for 
the set of companies for which data is available (23.1%), is 
led by increases in high R&D intensive sectors (33.8%) and 
medium-high sectors (26.3%), see figure S3.
Figure S3 - Employment figures in the Scoreboard, by sector group and main world region.
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Figures displayed refer only to those companies (477 EU, 574 US, 336 Japanese, 184 Chinese) for which data are available for both years 
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Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD
Box S.1 - Grouping of industrial sectors according to R&D intensity  (R&D  as % of net sales)*.
High R&D intensity sectors include mainly Pharmaceuticals & biotechnology; Health care equipment & services; 
Technology hardware & equipment; Software & computer services, Aerospace & defence and Leisure Goods.
Medium-high R&D intensity sectors include mainly Electronics & electrical equipment; Automobiles & parts; 
Industrial engineering; Chemicals; Personal goods; Household goods; General industrials; Support services.
Medium-low R&D intensity sectors include mainly Food producers; Beverages; Travel & leisure; Media; Oil equipment; 
Electricity; Fixed line telecommunications.
Low R&D intensity sectors include mainly Oil & gas producers; Industrial metals; Construction & materials; Food & 
drug retailers; Transportation; Mining; Tobacco; Multi-utilities.
* This classification takes into account the R&D intensity of all companies aggregated by ICB 3-digit sectors:  High above 5%; Medium-high between 
2% and 5%; Medium-low between 1% and 2% and Low below 1%. Some sectors are adjusted to compensate for insufficient representativeness 
of the Scoreboard using the OECD definition of technology intensity for manufacturing sectors (ISIC REV 3. Technology intensity definition, OECD, 7 
July, 2011.)
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As in the previous Scoreboard edition, the top R&D 
investors are Volkswagen, Samsung, Microsoft, Intel 
and Novartis. The most significant changes at the top 
of the ranking in 2014 are the climb of Google to 6th 
place (from 9th), and Pfizer to 10th place (from 15th). 
Huawei (15th) and Apple (18th) accelerated in 2014 
their race towards the top 10, jumping 11 and 17 
positions, respectively. 
Companies in the ICT, Pharmaceuticals and Automobiles 
sectors continue to dominate the top 10 of the ranking. The 
slip down in the ranking of the EU based companies present 
in the top 50 is in part due to the depreciation of the euro 
which started in the second half of 2014 (see Box I.1 for 
further detail).
Most of the top 100 companies showing a double-digit R&D 
increase are in the Pharmaceuticals & Biotechnology (10), 
ICT (9) and Automobiles & Parts (6) sectors. The companies 
showing the largest increase in R&D are Tata Motors, India 
(108.9 %);  Facebook, US (88.4 %); Total, France (42.6 %); SK 
Hynix, South Korea (37.2 %) and Apple, US (35.0 %).
Among the top 100 companies, 21 have at least doubled 
their R&D since the beginning of the crisis in 2008 (3 
companies based in the EU, 10 from the US and 8 from 
other countries). This group of companies is mainly from 
high R&D-intensive sectors (12) and from medium-high R&D 
intensive sectors (5). Many of these companies have also 
shown outstanding sales and employment performance in 
the period 2008-2014 (twelve doubled net sales and seven 
doubled employment). 
In some cases the big changes in R&D observed over the 
last ten years are the result of different corporate policies 
such as mergers & acquisitions (M&As). Google and Oracle, 
with 122 and 65 deals respectively, illustrate this corporate 
behavior in the ICT sector. In terms of total value of the deals, 
pharmaceuticals companies dominate the ranking of M&As 
over the past eight years (Pfizer, Merck, Roche and Novartis). 
EU and US based companies show a higher degree of 
internationalisation of their inventive activities, with 
26% and 22% of their patent families developed by 
inventors located outside the region. The share of EU 
owned patent families developed by inventors located 
in the US (19%) is higher than the share of US patent 
families developed by inventors in the EU (10%).
The country distribution of patents filed by the world’s top 
R&D investors is a good proxy for the location of companies’ 
innovation activities. The analysis shows that 80% of patents 
were developed by inventors residing in the same world 
region as the parent company owning the rights.
Interesting regional and sector specificities have been found, 
both in the degree of internationalisation of companies’ 
innovation activities and in the capacity of attracting R&D 
investments. Such differences reflect the industrial and 
technological specialisation of the world regions. The US 
appears to be the most attractive region of the world for 
the R&D investment for health related sectors, pharma 
and biotech in particular (Figure S.4). Europe is instead the 
preferred international location for the inventive activity of 
automobile companies (Figure S.5). This holds true for US 
based companies (28%) and particularly for those based in 
the rest of the world (71%).
Table S.4 - Mapping the international location of patenting activities (Pharmaceuticals & Biotech).
Inventor location 
EU USA Japan RoW Switzerland
Co
m
pa
ny
’s
 h
ea
dq
ua
rt
er
 lo
ca
tio
n
EU 
(6,635)
72.2% 21.6% 1.3% 3.9% 1.0%
USA 
(8,619)
10.3% 81.2% 1.7% 5.0% 1.8%
Japan 
(1,342)
5.8% 18.5% 67.8% 7.7% 0.21%
RoW 
(860)
18.1% 30.5% 0.1% 50.3% 1.12%
Switzerland 
(2,897)
31.0% 43.7% 2.6% 3.8% 18.8%
Note:  Patent families are fractional counted in case of multiple inventors and/or multiple applicants. RoW does not include Switzerland as in other parts 
of the present report. 
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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Companies in the high-tech sectors of Health and ICT 
showed a robust R&D growth in 2014 (Software 12.8%, 
Hardware 6.7%, pharma & biotech 7.2%). This has been 
driven mainly by the strong performance of US based high-
tech companies, which continued to increase their share 
in the country’s Scoreboard sample. The Pharma sector 
recovered in 2014 from the 2013 sluggish performance 
in both the US and the EU. 
High R&D-intensive sectors showed a strong R&D investment 
performance worldwide, supported by robust sales growth. 
Companies based in the US and operating in ICT sectors continued 
to strongly increase their R&D investments, well above the growth 
rate of their competitors based in the EU and Japan: Software 
13.1% versus 4.6% for EU and -5.7% for Japan, Hardware 7.0% 
versus -1.7% in EU and 1.3% in Japan.  Companies located in the 
rest of the world showed outstanding performances in terms of 
R&D investment growth in ICT sectors (34.4% for Software and 
16.7% for IT-hardware). These performances are mainly driven 
by companies based in China (47.3% and 24.8%) and South 
Korea (11.7% and 29.9%).
The R&D investment performance of the pharma and biotech 
sector in 2014 of companies based in the US (10.7%) and the 
EU (6.5%) is much better than that observed in 2013 (0.4% and 
0.9% respectively). Pharma companies based in Japan showed 
an inverse trend: poor performance in 2014 (-1.0%) compared to 
the good performance in 2013 (9.3%).
These trends enhance US specialisation in high R&D intensive 
sectors and increase the gap with respect to its main competing 
companies in the EU and Japan. Meanwhile, companies based in 
China and South Korea are catching-up quickly.
US Scoreboard companies operating in high R&D-intensive 
sectors invest more than their EU counterparts, as illustrated in 
figure S.6. The most striking differences, both in terms of number 
of companies and overall R&D investment values, correspond to 
the Software, Internet and Computer Services, ICT Hardware, and 
to the health related sector of Biotechnology.
As shown in figure S.6 below, there is a significant gap for 
the EU vis-à-vis the US in terms of number of companies 
and R&D investment in high-tech sectors related to 
health and ICT. Nevertheless, the Scoreboard also shows 
a number of world-beating EU companies of substantial 
size in these sectors, as well as a significant number of 
high-performance companies showing the potential to 
further climb-up in the ranking of world top R&D investors.
There are a number of world-beating EU companies of 
substantial size in high-tech sectors related to health and ICT, 
such as Novo Nordisk (DK) in health, or ASML (NL) and ARM (UK) 
in ICT. Evidence from the EU enlarged Scoreboard sample shows 
a relevant number of high-performance R&D based innovators. 
Among these smaller R&D investors, five show particularly 
strong R&D intensity (above 10%) coupled with strong net sales 
growth (above 10% in the period 2005-2013), positive profits 
and well above sectoral labour productivity average: Dialog 
Semiconductor, Gameloft, Generix, Playtech and Wirecard. The 
challenge for Europe is to create the conditions needed to favour 
the sustained growth of such companies and the emergence and 
high growth of new ones. 
Overall, the R&D growth of EU companies outperform 
their US counterparts in medium-high tech sectors, 
however a mixed performance is shown in both regions.
In particular in the EU, a strong R&D performance of the EU 
Automobiles sector in 2014 (7.9%) has been offset by a negative 
one in Industrial Engineering (–4.1%, largely explained by the 
figures of the largest R&D investors in this sector Volvo -4.4% 
and Alstom – 59.5%), General Industrials (-2.1%) and Chemicals 
(-0.8%).
Interestingly, the R&D intensity of key medium-high tech sectors 
in the EU is generally higher than that of the US (see Figure 
Table S.5 - Mapping the international location of patenting activities (Automobiles and Parts).
Inventor location 
EU USA Japan Asian Tigers RoW
Co
m
pa
ny
’s
 h
ea
dq
ua
rt
er
 
lo
ca
ti
on
EU  
(14,609)
84.9% 10.6% 1.2% 0.9% 2.4%
USA 
(7,172)
28.1% 65.8% 0.8% 0.4% 4.8%
Japan 
(17,508)
1.6% 7.8% 89.9% 0.0% 0.58%
Asian Tigers (2,520) 0.2% 0.8% 0.4% 97.0% 1.54%
RoW 
(118)
71.4% 5.3%   23.3%
Note:  Patent families are fractional counted in case of multiple inventors and/or multiple applicants. RoW does not include the Asian Tigers and 
Switzerland as in other parts of the present report.
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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S.7). In this respect, the Automobiles and Electronic & Electrical 
Equipment sectors in the EU show an R&D intensity above the 
5% threshold used for classifying a sector as high-tech (share of 
R&D over net sales): 5.5% and 5.2%, respectively. Also in terms 
of overall R&D investments the EU outperforms the US in the 
medium-high tech sectors (€76.2bn vs €46.9bn).
Figure S.7 R&D investment and R&D intensity for selected medium high-tech sectors (EU vs US).
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Figure S.6 - R&D investment and R&D intensity for selected high-tech sectors (EU vs US).
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Introduction
This 2015 edition of the “EU Industrial R&D Investment 
Scoreboard” (the Scoreboard)3 comprises the 2500 
companies investing the largest sums in R&D in the 
world and an additional number of companies to cover the 
top 1000 R&D investing companies based in the EU4. 
In total, there are 2898 companies incorporated in the 2015 
Scoreboard.  
Companies’ R&D rankings are based on information taken 
from the companies’ latest published accounts. For most 
companies these correspond to calendar year 2014, but 
significant proportions have financial years ending on 31 
March 2015 (Japanese companies in particular). There are 
few companies included with financial years ending as late 
as end June 2015 and a few for which only accounts to end 
2013 were available.
In order to avoid double counting, The Scoreboard considers 
only data from parent or independent companies. Normally, 
these companies integrate into their consolidated accounts 
the data of their subsidiary companies. An analysis of the 
ownership structure of the parent companies included in the 
2015 Scoreboard shows that they have more than 600.000 
subsidiary companies (controlled companies with more than 
50% ownership).
It should be noticed that the Scoreboard relies on disclosure of 
R&D investment in companies’ published annual reports and 
accounts and that due to different national accounting and 
disclosure practices, companies of some countries are less 
likely than others to disclose R&D investment consistently. 
For these reasons, companies from some countries such as 
Southern or Eastern European countries might be under-
represented while others such as the companies from the 
UK over-represented.  
The Scoreboard collects key information to enable the 
assessment of the R&D and economic performance of 
companies. The main indicators, namely R&D investment, 
3  The EU Industrial R&D Investment Scoreboard is published annually by the European 
Commission (JRC-IPTS/DG RTD) as part of its Industrial Research and Innovation 
Monitoring and Analysis activity (IRIMA). 
4  In this report, the term EU company refers to companies whose ultimate parent has 
its registered office in a Member State of the EU. Likewise, non-EU company applies 
when the ultimate parent company is located outside the EU (see also the glossary and 
definitions in Annex 2 as well as the handling of parent companies and subsidiaries).
net sales, capital expenditures, operating profits and number 
of employees are collected following the same methodology, 
definitions and assumptions applied in previous editions. This 
ensures comparability so that the companies’ economic and 
financial data can be analysed over a longer period of time. 
The capacity of data collection is being improved by 
gathering information about the ownership structure of 
the Scoreboard parent companies and the main indicators 
for their subsidiaries.  In 2015, we have collected available 
indicators reported by the more than 600.000 subsidiary 
companies involved in this Scoreboard edition. This allows a 
better characterisation of companies, in particular regarding 
the sectoral and geographic distribution of their research 
and production activities and the related patterns of growth 
and employment. 
In particular, the analysis of key indicators on the parent 
companies and their subsidiaries allows the reassignment 
of companies to countries where they show their actual 
economic activity, thus improving our analyses at country and 
world region levels. For example, in this report, a significant 
number of companies have been reassigned to China as a 
result of the examination of companies headquartered in 
Cayman Island and Bermuda (see details in chapter 5).
Companies’ behaviour and performance can be analysed 
over longer time periods using our history database that 
contains information on the top R&D companies since 
2003. This enables benchmarking analyses of companies 
across sectors and countries, for example the identification 
of companies showing outstanding economic or innovation 
results and the analysis of the main factors underlying such 
successful dynamics.
The data have been collected by Bureau van Dijk Electronic 
Publishing GmbH, following the same approach and 
methodology applied since the first Scoreboard edition in 
2004. For background information please see Annex 1.  
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Report structure 
Chapter 1 presents the worldwide trends of industrial R&D. 
It provides an overview of the main indicators for the top 
2500 companies ranked by level of R&D investment and the 
main changes that took place over the last year. An analysis 
of the main indicators of the company data aggregated by 
world regions is included together with the performance of 
companies over the past 10 years.
The performance of individual companies among the top 
R&D investors is provided in chapter 2. The list of the top 
world 100 R&D companies is examined highlighting those 
companies showing remarkable R&D and economic results 
and improvement in the R&D ranking over the last 12 years.
Chapter 3 presents an analysis of the main R&D and economic 
indicators of companies aggregated by industrial sector, with 
comparisons of EU companies and their main worldwide 
counterparts. 
Results of an analysis aimed at identifying companies that 
presented outstanding economic and R&D performance over 
the past 10 years is shown in chapter 4. The analysis includes 
a discussion of corporate characteristics that likely contributed 
to the high performance of these companies.
Chapter 5 deals with the international distribution of 
companies’ economic and innovation activities. The objective 
is to obtain a first estimate of the actual distribution of jobs, 
value-added and knowledge across countries and regions. 
Chapter 6 discusses the trends on R&D and economic 
performance of the companies included in the extended 
sample comprising the top 1000 R&D investors based in the 
EU. This includes the results of an exercise aiming to extend 
the coverage of R&D investing companies in member states 
previously thought to be under-represented in the Scoreboard.
Annex 1 provides background and methodological information 
about how the Scoreboard is prepared. The methodological 
approach of the Scoreboard, its scope and the limitations are 
described in Annex 2.  The sector and country composition of 
the EU 1000 sample is found in Annex 3. A supplementary list 
of companies reporting R&D investment is presented in Annex 
4.  The access to the full dataset is shown in Annex 5. 
The complete data set is freely accessible online at: http://iri.
jrc.ec.europa.eu/scoreboard15.html
Description of the company 
dataset
This edition of the Scoreboard contains data on the world’s 
top 2500 companies ranked by their investments in R&D. 
These companies each invested more than €17.9 million in 
2014/15, accounting together for €607.2 billion. 
The amount of R&D investment by these 2500 companies is 
equivalent to more than 55% of the total expenditure on R&D 
worldwide (GERD) and about 90% of the R&D expenditure 
financed by the business sector worldwide (BERD). This is 
illustrated in figure I.1 where the latest 2013 territorial 
statistics are compared with the corresponding figures of 
the 2014 Scoreboard (2014 Scoreboard €538.3bn; GERD 
€973.6bn; BERD €604.9bn).
Figure I.1 - Comparison of R&D figures of the Scoreboard and territorial statistics.
 Note: Total R&D expenditure (GERD) and total business R&D expenditure (BERD) funded by the business sector in 2013.
Sources: Latest figures reported by Eurostat (30 March 2015) including most countries reporting R&D.  
                The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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The dataset is complemented with additional companies 
in order to cover the top 1000 R&D investing companies 
based in the EU, all of them having invested more than R&D 
€5.5 million in 2014. This additional sample is analysed 
separately in chapter 6. 
The main methodological limitations are summarised in Box 
I.1 (see further description of the dataset in Annex 2).
Companies’ distribution by country, industry and size 
classes
The 2015 Scoreboard comprises companies with 
headquarters in 44 countries of which 19 are member 
states of the EU. The sample includes companies based in 
the EU (608), the US (829), Japan (360) and other countries 
(703) including China (301), Taiwan (114), South Korea (80), 
Switzerland (55), Canada (27), Israel (27), India (26) and a 
further 16 countries. See Table I.1 and Figure I.4.
A wide range of manufacturing and services sectors is 
represented in the Scoreboard, including 41 industries5 with 
a special focus on the most innovative ones such as ICT, 
health, transport and engineering related industries. See 
number of EU and non-EU companies in Table I.2 and the 
top 3 companies by level of R&D investment for the main 
industries in Table I.3.
The distribution of the 2500 sample by groups of companies 
in terms of number of employees is shown in Table I.4.    
5 Sectors classified according to the Industry Classification Benchmark (3 digits level 
of aggregation).
Table I.1 - Distribution of companies by country. 
Number of companies by country
EU non-EU
Germany 136 US 829
UK 135 Japan 360
France 86 China 301
Sweden 42 Taiwan 114
The Netherlands 42 South Korea 80
Italy 32 Switzerland 55
Denmark 25 Canada 27
Finland 22 Israel 27
Ireland 20 India 26
Spain 17 Australia 16
Belgium 16 Norway 10
Austria 14 Brazil 9
Luxembourg 7 Singapore 9
Portugal 5 Turkey 9
Greece 3 Malaysia 5
Czech Republic 2 Russia 3
Slovenia 2 New Zealand 2
Hungary 1 Saudi Arabia 2
Malta 1 Further 7 countries 8
Total 608 Total 1892
Note: 2500 companies with R&D investment above €18.0 million.
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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Table I.2 - Distribution of companies by industrial sector.
Number of companies in the 10 most numerous industries
EU non-EU
Pharma & Biotech 70 Tech Hardware & Equip. 281
Industrial Engineering 68 Pharma & Biotech 246
Soft. & Computer Services 46 Soft. & Computer Services 229
Electronic & Electric Equip. 45 Electronic & Electric Equip. 184
Automobiles & Parts 35 Industrial Engineering 133
Tech Hardware & Equip. 35 Automobiles & Parts 120
Chemicals 24 Chemicals 109
Banks 23 Health Care Equip. & Services 80
Aerospace & Defence 21 General Industrials 76
General Industrials 21 Construction & Materials 53
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
Table I.3 - Top 3 companies for the main industries included in the 2015 Scoreboard.
Pharmaceuticals & Biotech. Automobiles & Parts Technology Hardware & Equip.
NOVARTIS Switzerland VOLKSWAGEN Germany INTEL US
ROCHE Switzerland TOYOTA MOTOR Japan CISCO SYSTEMS US
JOHNSON & 
JOHNSON
US GENERAL MOTORS US APPLE US
Software & Computer Services Electronic & Electrical Equipment Industrial Engineering
MICROSOFT US SAMSUNG South Korea VOLVO Sweden
GOOGLE US SIEMENS Germany CATERPILLAR US
ORACLE US HITACHI Japan ABB Switzerland
Chemicals Aerospace & Defence General Industrials
BASF Germany AIRBUS
The 
Netherlands
GENERAL ELECTRIC US
DUPONT US BOEING US TOSHIBA Japan
MONSANTO US
UNITED 
TECHNOLOGIES
US PHILIPS
The 
Netherlands
Leisure Goods Health Care Equipment & Services Oil & Gas Producers
SONY Japan MEDTRONIC PLC Ireland PETROCHINA China
PANASONIC Japan
BAXTER 
INTERNATIONAL
US TOTAL France
LG ELECTRONICS South Korea BOSTON SCIENTIFIC US
ROYAL DUTCH 
SHELL
UK
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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Concentration of the R&D investment by company, 
sector and country
Industrial R&D is highly concentrated.  A small subset of 
companies, industries and countries account for a large 
share of the total R&D investment of the 2500 sample. 
For example, the top 100 companies account for 53.2%, 
the companies based in the three largest countries (US, 
Japan and Germany) account for 62.8% and the four largest 
industries (Pharmaceuticals & Biotechnology, Automobiles 
& Parts, Technology Hardware & Equipment, Software & 
Computer Services) account for 59.8% of the total R&D 
investment. This is illustrated in Figures I.2 and I.3.
Table I.4 - Distribution of companies in the 2015 Scoreboard by size class.
Number  of 
employees
Number  of 
companies
R&D per 
company (€m)
Net sales per company 
(€m)
R&D intensity 
(%)
Less than 
250(SMEs)
142 39.1 799.8 4.8
251-1000 241 42.1 215.7 19.5
1001-5000 572 63.5 911.9 7
5001-10000 381 142.1 2793.2 5.1
More than 10000 866 517.2 16740.6 3.1
 Note:  Figures have been computed on 2202 out of the 2500 companies for which data on employment 2014 are available.
 Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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Figure I.2 - Companies of the 2015 Scoreboard ranked by R&D.
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Figure I.3 - R&D investment of the 2015 Scoreboard aggregated by country.
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Figure I.4 Distribution of the 2500 companies in the 2015 Scoreboard by country.
    
Note: The world map only includes countries with 9 or more companies. 
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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6 Since 2005, the European Union requires all listed companies in the EU to prepare their consolidated financial statements according to IFRS (see: EC Regulation No 1606/2002 
of the European Parliament and of the Council of 19 July 2002 on the application of international accounting standards at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri
=CELEX:32002R1606:EN:HTML).
Box I.1 Methodological caveats.
Users of Scoreboard data should take into account the methodological limitations summarised here,  especially when 
performing comparative analyses (full description of methodology is found in Annex 2): 
A typical problem arises when comparing data from different currency areas.  The Scoreboard data are nominal and 
expressed in Euros with all foreign currencies converted at the exchange rate of the year-end closing date (31.12.2014). 
The variation in the exchange rates from the previous year directly affects the ranking of companies, favouring those 
based in countries whose currency has appreciated with respect to the other currencies. In this reporting period, the 
exchange rate of the Euro depreciated by 12.3% against the US dollar and by 7.1 % against the pound sterling. The 
Japanese Yen remained practically unchanged. 
The growth rate of the different indicators for companies operating in markets with different currencies is affected 
in a different manner. In fact, companies’ consolidated accounts have to include the gains and/or losses due to the 
appreciation and/or depreciation of their investments abroad. The result is an ‘apparent’ rate of growth of the given 
indicator that understates or overstates the actual rate of change. For example, this year the R&D growth rate of 
companies based in the Euro area with R&D investments in the US is partly overstated because the ‘gains’ of their 
overseas investments due to the depreciation of the Euro against the US dollar (from $1.38 to $1.21). Conversely, the 
R&D growth rate of US companies is partly understated due to the ‘losses’ of their investments in the Euro area. Similar 
effects of understating or overstating figures would happen for other indicators, e.g. for net sales. 
When analysing data aggregated by country or sector, be aware that in many cases, the aggregate indicator depends 
on the figures of a few firms. This is due, either to the country’s or sector’s small number of firms in the Scoreboard or 
to the indicator being dominated by a few large firms.
The different editions of the Scoreboard are not directly comparable because of the year-on-year change in the 
composition of the sample of companies, i.e. due to newcomers and leavers. Every Scoreboard comprises data for 
several financial years allowing analysis of trends for the same sample of companies.
In most cases, the companies’ accounts do not include information on the place where R&D is actually performed; 
consequently the approach taken in the Scoreboard is to attribute each company’s total R&D investment to the country 
in which the company has its registered office or shows its main economic activity. This should be borne in mind when 
interpreting the Scoreboard’s country classification and analyses.
Growth in R&D can either be organic, the outcome of acquisitions or a combination of the two. Consequently, mergers, 
acquisitions and demergers may sometimes underlie sudden changes in specific companies’ R&D growth rates and/or 
positions in the rankings. 
Other important factors to take into account include the difference in the various countries’ (or sectors’) business cycles 
which may have a significant impact on companies’ investment decisions, and the initial adoption or stricter application 
of the International Financial Reporting Standards (IFRS)6. 
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This chapter provides an overview of the main trends for R&D 
and economic indicators of the world 2500 companies that 
each invested more than €18.0 million in R&D in 2014/157. 
It includes analysis of the performance of companies 
aggregated according to the location of their registered 
offices in the main world regions.  The 2500 companies are 
grouped into four main sets: the top 608 companies from 
the EU, 829 companies from the US, 360 from Japan and 
703 companies from other countries (RoW group). ‘Other 
countries’ includes companies from China (301), Taiwan 
(114), South Korea (80), Switzerland (55) and companies 
based in a further 19 countries.
As in the previous year, the average growth rate of companies’ 
R&D investments in 2014 was significantly higher than the 
growth rate of their revenues. 
R&D investments and economic results in 2014 show 
important variations across world regions, countries 
and industries.  As observed in recent years, this reflects 
a continued weak and uneven recovery of the global 
economy and persistent market uncertainties. Box 1.1 below 
summarises the economic background in 2014 and early 
2015 in which global R&D companies have been operating.
7 Due to data availability some companies may be missed, please see methodological 
limitations in Annex 2.
Key findings
• The top 2500 Scoreboard companies invested €607.2bn 
in R&D, 6.8% more in 2014 than in 2013, following the 
increase of 5.0 % in the year before. The net sales of the 
2500 companies were €17 972.6bn and increased much 
less than R&D, at 2.5 %, the same net sales increase as in 
2013. The lower increase in companies’ sales was driven 
by falls in the prices of oil & gas and metals.
• The 608 EU companies increased R&D investment by 3.3% 
to €170.9bn while decreasing net sales by 1.0 %. The 
829 US companies invested €232.2bn in R&D, a higher 
increase respect to the previous year (8.1 %) but a lower 
increase in net sales (3.6%). The 360 Japanese companies 
showed a different performance, increasing R&D by 2.6% 
to €86.6bn but with a higher increase in net sales of 4.3%. 
• As in the previous period, companies outside of the EU, 
the US and Japan (the RoW group) showed the best 
performance in terms of R&D (13.1%) while increasing net 
sales by 3.7 %. The largest increases in R&D investment 
in this group were reported by companies based in China 
(23.6 %), Taiwan (12.4 %) and South Korea (10.6 %).
• The Chinese companies, the 3rd largest country by number 
of companies (301) in this edition (but the 4th largest 
by amount of R&D), showed outstanding results in the 
IT-hardware and software sectors. For example, Baidu, 
Lenovo, Tencent, Huawei and ZTE had double-digit R&D 
and net sales growth.
• Trends over the past 9 years show a hesitant recovery of 
companies based in the EU, especially in terms of net sales 
whereas their the US counterparts seem to have returned 
to the high R&D investment levels that obtained prior to 
the crisis.  Japanese companies, hardly affected by the 
crisis, show positive results in terms of R&D, net sales and 
profitability over the last two years, indicating continuing 
recovery after the earthquake of 2011.
1 Worldwide trends in corporate R&D
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    Source:  Innovomantex Ltd.  
Box 1.1 Economic background for the Scoreboard companies in 2014.
The economic situation tends to be dominated by the performance of the largest economies. The top five (US, China, 
Japan, Germany and the UK) account for almost 51% of world GDP with the top ten (which adds in France, Brazil, Italy, 
Russia & India) contributing just over 65%*. Brazil, Russia and India have few R&D companies in the Scoreboard.
These are main trends and factors affecting the major economies:
• The US and UK economies were the fastest growing Western ones, helped by the early use of QE (quantitative 
easing). The US Fed ended its five year QE programme in October 2014 and since then there has been speculation 
about when the first US interest rate rise would occur (but it had still not happened as of October 2015). The prospect 
of early rate rises in the US and UK have meant that both the dollar and sterling have remained strong.  
• Japan unleashed a massive QE programme in April 2013 and this has led to a weak yen but with inflation still 
remaining worryingly low. The ECB launched its QE programme in March 2015, later than the US, UK and Japan. In 
autumn 2015, Eurozone growth was still substantially lower than in the US or UK and unemployment was running 
at around twice US/UK levels. The continuing QE programme has resulted in the euro falling against both the dollar 
and sterling.
• China’s growth rate has been slowing and probably more than the official statistics suggest since the country’s 
growth rate supposedly continued to hit its target in Q1 2015 despite slowing industrial production and a slumping 
property market**. The slowing Chinese economy has been affecting Western companies’ growth, the lower demand 
for metals and falling metals prices being a related effect of this in 2014 and 2015. Of the other BRICs, Brazil is 
already in recession and Russia is suffering from the drop in oil and commodity prices.
• Oil prices were around $100 per barrel in mid-2014 but then started to fall and reached $50 at the end of the 
year. They have remained in the range $45 to $60 throughout 2015. This has benefited fuel using industries such 
as airlines and road transport but has provided a strong headwind for oil companies and engineering companies 
supplying the equipment for oil exploration and production activities.
These trends have had some significant effects in the table of the top 50 global R&D investors by amount of R&D. 
The stronger dollar means that many US companies have moved up a few places in the global rankings from last year 
whereas the weaker yen has seen many Japanese (and, to a lesser extent, Eurozone companies) moving down. And 
most companies with substantial sales to BRIC countries and to the oil & gas sector have experienced slowing growth.
*Statistics Times.com
**The Economist
1  W o r l d w i d e  t r e n d s  i n  c o r p o r a t e  R & D
23
1.1 Indicator changes over the 
last year
The main economic and financial indicators for the year 2014 
for the set of 2500 companies are summarised in Table 1.1. 
• The positive trends on R&D investment continued in 2014 
for the fourth consecutive year. The 2500 Scoreboard 
companies invested €607.2 billion in R&D, 6.8 % more 
than in 2013, following the increase of 5.0% in the year 
before. Seventy three per cent of the companies showed 
positive R&D growth in 2013.  
• For the third consecutive year, the net sales of the 2500 
companies increased less than R&D, at 2.2 %, a similar 
net sales increase as in the previous period. Company 
results in terms of operating profits improved significantly 
compared with the previous year:  82% of companies 
made profits - a much larger proportion than the 18% of 
companies that reported losses - but slightly down on the 
83% reported last year.
• Company investment in fixed capital remained unchanged, 
compared with the previous year’s increase of 2.8 %. 
Capital expenditure as a percentage of net sales (7.1 %) 
remained practically the same as that of the previous year.
• The number of employees of the 2500 companies in the 
Scoreboard increased by 1.5 %. 
Table 1.1 - Overall performance of the 2500 companies in the 2015 Scoreboard.
 Factor Top 100 R&D investors world 2500
R&D  in 2014, € bn 323.4 607.2
One-year change, % 6.4 6.8
CAGR 3yr, % 6.1 6.1
Net Sales, € bn 5 125.6 17 972.6
One-year change, % 2.5 2.2
CAGR  3yr, % 4 2.9
R&D intensity, % 6.3 3.4
Operating profits,  € bn 591.4 1 735.4
One-year change , % -1.7 0.5
Profitability, % 11.5 9.7
Capex, € bn 346.7 1 131.2
One-year change , % 0.8 -0.1
Capex / net sales, % 7 7.1
Employees, million 12.1 51.2
One-year change, % -1.2 1.5
Note: Profitability equals to Operating profits as percentage of sales.
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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1.2 R&D trends by world region
Figure 1.1 and table 1.2 summarise the companies’ indicators 
aggregated by main world region and table 1.3 shows the 
main indicators for countries included in the RoW group.
The R&D investment of the 608 EU companies continued to 
grow in 2014 at a significant pace, 3.3%, compared with 2.5 
% in 2013. As also observed last year, the net sales of the 
EU companies decreased slightly by 1.0%. This was driven 
by falls in the prices of oil & gas and mining products which 
form a larger proportion of EU companies’ sales than in other 
regions. The overall R&D and, to a smaller extent, the net 
sales of the EU group are largely driven by the performance 
of German companies that account respectively for 36.8% 
and 26.8% of the EU’s total R&D and net sales. The 136 
German companies in the EU-608 group increased R&D 
by 6.3% and net sales by 3.0%.  These results reflect to a 
large extent the performance of the German companies in 
the Automobiles & Parts sector (+7.8% in R&D and +6.2 % 
in net sales). This sector accounts for 53% of the R&D and 
34% of the net sales of the group of German companies. 
The other two largest member states of the EU showed a 
modest performance; companies based in the UK increased 
R&D by 0.3 % and decreased sales by 5.4% and those based 
in France increased R&D by 0.5% and decreased net sales by 
1.5%. The UK’s sales decrease was largely due to the fall in 
oil & gas and metals prices.
The group of US companies increased R&D investment (8.1 %) 
at a higher rate than the world’s average and increased net 
sales by 3.6 %. The R&D growth of the US companies was 
led by companies in high R&D-intensive sectors. Most of the 
largest US companies in Pharmaceuticals & Biotechnology 
and Software & Computer Services had double-digit R&D 
growth. Also some large companies in the Technology 
Hardware & Equipment sector such as Apple and Qualcomm 
showed high R&D growth (35.0% and 10.3% respectively).
Japanese companies underperformed EU and US firms, in 
terms of R&D (2.6 %) but showed a larger net sales growth 
(4.3 %).  As in the case of German companies, the average 
performance of Japanese companies is strongly dependent 
on the results of the Automobiles & Parts sector, accounting 
for 28.5 % of total Japanese R&D, which showed an increase 
of 6.6% in R&D and 7.8% in net sales.
Companies based outside of the EU, US and Japan (the 
RoW group) continued to increase substantially their R&D 
investment (13.1 %) and also net sales, at a more moderate 
rate but above the world average’s (3.7 %). The largest 
increase in R&D investment was reported by the 301 
companies based in China (23.6 %). In the Chinese group 
of companies, outstanding performance was shown by the 
largest R&D investor, Huawei that increased R&D by 33.8 % 
and by R&D increases in high tech sectors such as Software 
and Computer Services (47.3 %) and Technology Hardware 
& Equipment (24.8%). 
Other countries in the RoW group whose companies have 
showed large increases in R&D are Taiwan (12.4 %) and 
South Korea (10.6 %). The companies based in Switzerland, 
now the second largest R&D investor in this group, showed a 
modest increase in R&D (2.7 %). Swiss R&D is dominated by 
Novartis and Roche
Compared with last year’s Scoreboard, the EU and Japanese 
companies’ share of total R&D investment decreased by 2.0 
and 1.5 percentage points respectively (from 30.1% to 28.1% 
and 15.8% to 14.3%).  On the contrary, the R&D share of US 
companies increased by 2.2 percentage points and that of 
the other countries group by 1.4 percentage points. 
The average R&D intensity of companies based in the EU, the 
US and other countries increased by 0.2 percentage points 
due to the higher growth of R&D investments compared with 
the growth rate of net sales. The R&D intensity for companies 
based in Japan remained practically unchanged.  US R&D 
intensity is substantially larger than that of all regions 
because of its concentration in high technology sectors.
In 2014, average company capital expenditure decreased for 
the second consecutive year for EU and Japanese companies 
(-5.1% and -2.1% respectively). Companies based in the US 
continued to increase capital expenditure at a significant pace 
(5.7%) whereas those based in the RoW group increased it 
slightly (0.8%).       
Companies based in the EU showed a significant increase in 
operating profits (5.0%) reversing the negative trend of the 
previous years. The opposite happened for the companies 
based in the RoW group (-4.7%) and for the US companies 
(-0.8%). The Japanese companies showed for the second 
consecutive a significant increase in profits (8.2%).  The 
higher profits from Japanese companies are due mostly to 
the largest R&D investing sector, Automobiles & Parts (12 
%) and also IT-Hardware (21 %). The profitability (operating 
profits as percentage of net sales) changed according 
to the difference between the growth rate of sales and 
profits.  Consequently, the average profitability of the EU 
and Japanese companies increased (to 8.3% and 6.5% 
respectively) and those based in the US and the RoW group 
slightly decreased (to 13.5% and 9.8% respectively).  The 
ratio of sales to employees’ number was highest for the US 
and RoW groups where profitability was also higher.
As underlined in previous Scoreboard reports, most of 
the differences in R&D intensity and profitability between 
regions and countries are related to differences in sector mix. 
The US is by far the strongest region in the group of high 
R&D intensity sectors including pharmaceuticals, health, 
software, and technology hardware whereas the EU and 
Japan are stronger in medium R&D intensity sectors such as 
the automotive sector (see chapter 3).
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Figure 1.1 - R&D investment by the top 2500 companies, by main world region (% of total €607.2bn).
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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Table 1.2 - Overall performance of the 2500 companies in the 2015 Scoreboard.
Factor EU USA Japan RoW
No. of companies 608 829 360 703
R&D in 2014, € bn 170.9 232.2 86.6 117.5
World R&D share, % 28.1 38.2 14.3 19.4
One year change, % 3.3 8.1 2.6 13.1
CAGR 3yr, % 4.2 6.9 3.1 10.5
Net Sales, € bn 6 042.8 4 397.6 2 644.5 4 887.7
One year change, % -1.0 3.6 4.3 3.7
CAGR 3yr, % 0.0 2.6 6.8 5.3
R&D intensity, % 2.8 5.2 3.3 2.4
Operating Profit, € bn 491.9 593.8 172.9 476.9
One year change, % 5.0 -0.8 8.2 -4.7
Profitability, % 8.3 13.5 6.5 9.8
Capex, € bn 324.2 283 160.4 363.6
One year change, % -5.1 5.7 -2.1 0.8
Capex intensity, % 6.8 6.5 6.1 8.6
Employees, million 19.7 11.6 8.3 11.6
One year change, % 1.9 1.4 -0.9 3.1
Note: Profitability equals to Operating profits as percentage of sales.
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
Table 1.3 - Performance of companies based in the largest countries of the RoW group.
Factor China Switzerland South Korea Taiwan
No. of companies 301 55 80 114
R&D in 2014, € bn 36.1 24.9 23.8 12.2
World R&D share, % 5.9 4.1 3.9 2.0
One year change, % 23.6 2.7 10.6 12.4
CAGR 3yr, % 17.8 3.6 13.3 9.8
Net Sales, € bn 1894.7 346.7 936 478.4
One year change, % 5.9 1.0 -0.6 5.7
CAGR 3yr, % 7.4 2.1 4.4 3.5
R&D intensity, % 1.9 7.2 2.5 2.6
Operating Profit, € bn 129.6 52.9 54.4 31.6
One year change, % -2.1 -5.5 -16.1 28.6
Profitability, % 6.8 15.3 5.8 6.6
Employees, million 6.77 1.27 n.a. 0.55
One year change, % 4.6 1.0 13.8 -1.0
Notes: Profitability equals to Operating profits as percentage of sales.
             Many South Korean companies do not report number of employees.
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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1.2.1 Long-term performance of companies by world 
region
The annual growth rates of R&D investment and net sales 
and the profitability of companies based in the EU, the US, 
Japan and China are provided respectively in figures 1.2, 
1.3, 1.4 and 1.5 for the period 2006-2014. These figures 
are based on our history database comprising R&D and 
economic indicators over the whole 2006-2014 period for 
1509 companies (EU 457, US 611, Japan 345 and China 94). 
Figure 1.6 shows the R&D and net sales trends for the 
companies based in the rest of the world, focussing on the 
largest R&D countries in this group (Switzerland, South 
Korea and Taiwan).
The trends observed in these figures show the behaviour 
of these companies including the effects of the crisis that 
began in 2008. The following points are observed:
• Companies based in the EU this year reversed the negative 
trends of the last three years, showing a modest recovery 
of R&D investment and diminishing the losses in net sales 
observed in the previous period.  The profitability of the EU 
companies also shows a slight increase over the last year. 
• The US companies continued to show significant R&D 
investment growth, similar to the level prior to the crisis 
and show a relative recover of net sales growth, but this 
was still well below the level of R&D growth. The US-based 
companies continued to show the high level of profitability 
that has been stable since recovery from the crisis in 2010. 
The profitability of the US companies is now close to 15% 
and much higher than their Japanese and EU counterparts 
in the range 6% to 9%.
• Japanese companies, hit hard by the crisis in 2008-2009 
and by the earthquake in 2011, continued their recovery, 
in R&D and especially in net sales, observed in the past 
period but at a more moderate pace. The profitability of 
Japanese companies also continued to recover in 2014 but 
remained at low levels, especially compared with that of 
the US companies. 
• R&D investment by the Chinese companies rose 
significantly over the period 2008-2010 and remained at 
high levels in recent years. On the contrary, their net sales 
slowed down during the crisis, picked up again and then 
decelerated again in the past three years. The profitability 
of the Chinese companies is lower than that of their US 
and EU counterparts and shows a smooth decreasing trend 
over the whole 2006-2014 period. Chinese profitability 
is slightly lower than that of the Japanese companies 
in 2014, significantly lower than the EU and much lower 
than the US. However, we have data for only 94 Chinese 
companies over the whole period compared to the 301 
firms listed in this year’s Scoreboard.
Figure 1.2 -  One-year growth rate of R&D investment and net sales and yearly level of profitability for the 
EU companies.
Note:  Figures for the three variables have been computed on 457 out of the 608 EU companies for which data are available for the entire period 
2007-2014
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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Figure 1.3 -  One-year growth rate of R&D investment and net sales and yearly level of profitability for the 
US companies.
Note:   Figures for the three variables have been computed on 611 out of the 829 US companies for which data are available for the entire period 
2007-2014
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
Figure 1.4 -  One-year growth rate of R&D investment and net sales and yearly level of profitability for the 
Japanese companies.
Note:   Figures for the three variables have been computed on 345 out of the 360 Japanese companies for which data are available for the entire 
period 2007-2014
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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Figure 1.5 -  One-year growth rate of R&D investment and net sales and yearly level of profitability for the 
Chinese companies.
Note:   Figures for the three variables have been computed on 94 out of the 301 Chinese companies for which data are available for the entire period 
2007-2014.   Please note the different scale respect to the 3 previous charts.
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
Figure 1.6 - One-year growth rate of R&D investment and net sales, by main world region.
Note:   Figures for the two variables have been computed on 53 Swiss, 61 South Korean, 105 Taiwanese and 105 RoW companies for which data are 
available for the entire period 2009-2014. The RoW group in this chart does not include companies located in China, Switzerland, South Korea 
and Taiwan.  Please note the different time scale respect to the 4 previous charts.
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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1.2.2 R&D trends by world regions and sector groups  
Trends in R&D over the long-term are presented in figure 1.7 
for the main world regions. The figures refer to a set of 1920 
companies that reported R&D over the whole period 2006-
2014 (EU-481, US-645, Japan-349 and RoW group-445). 
The R&D data are broken down into groups of industrial 
sectors with characteristic R&D intensities (see definition in 
Box 1.2). 
The following points can be observed regarding the overall 
R&D changes in the period 2006-2014 (figure 1.7): 
• The world 1920 companies increased R&D by 50.9 % (EU-
481 41.3 %; US-645 58.7 %; Japan-349 8.7 % and RoW 
group-445 131.5 %).
• For the 481 EU companies, the main R&D increases were 
in low R&D-intensive sectors (61.0 %) and medium-high 
sectors (44.4 %).   
• For the 645 US companies, the main R&D increases were 
in medium-low R&D-intensive sectors (97.3 %, but these 
represent a small proportion of total R&D) and high sectors 
(67.3 %). 
• For the 349 Japanese companies, the main R&D increases 
were in medium-high R&D-intensive sectors (14.8 %) and 
medium-low sectors (3.1 %). 
• For the 445 companies based in the rest of the world, the 
main R&D increases were in low R&D-intensive sectors 
(169.7 %) and medium-high sectors (141.6 %). 
• The proportion of high to medium R&D has increased for 
the US but decreased for both the EU and Japan.
Box 1.2  - Grouping of industrial sectors according to R&D intensity  (R&D  as % of net sales)*.
High R&D intensity sectors include mainly Pharmaceuticals & biotechnology; Health care equipment & services; 
Technology hardware & equipment; Software & computer services, Aerospace & defence and Leisure Goods.
Medium-high R&D intensity sectors include mainly Electronics & electrical equipment; Automobiles & parts; 
Industrial engineering; Chemicals; Personal goods; Household goods; General industrials; Support services.
Medium-high R&D intensity sectors include mainly Electronics & electrical equipment; Automobiles & parts; 
Industrial engineering; Chemicals; Personal goods; Household goods; General industrials; Support services.
* This classification takes into account the R&D intensity of all companies aggregated by ICB 3-digit sectors:  High 
above 5%; Medium-high between 2% and 5%; Medium-low between 1% and 2% and Low below 1%. Some sectors 
are adjusted to compensate for insufficient representativeness of the Scoreboard using the OECD definition of tech-
nology intensity for manufacturing sectors (ISIC REV 3. Technology intensity definition, OECD, 7 July, 2011.)
1  W o r l d w i d e  t r e n d s  i n  c o r p o r a t e  R & D
31
1.2.3 Employment trends by regions and sector groups
Among the 2500 sample in this year’s Scoreboard, 2202 
companies reported employee figures. In total these 
companies employed 51.2 million people in 2014, 1.5% 
more than the previous year. The distribution of employees 
by region was 19.7 million in the 584 companies based in 
the EU, 11.6 million in the 810 US companies, 8.3 million in 
the 357 Japanese companies and 11.6 million in the 451 
companies from other countries.  
Trends on employment over the long-term are presented in 
figure 1.8 for the main world regions. The figures refer to a set 
of 1689 companies that reported number of employees over 
the whole period 2006-2014 (EU-477, US-574, Japan-336 
and RoW group-302) and are broken down into groups of 
industrial sectors with characteristic R&D intensities (see 
definition in Box 1.2). 
The following points can be observed regarding the changes 
in number of employees in the period 2006-2014 (figure 
1.8): 
• Overall worldwide employment increased by 23.1% from 
2006 to 2014 led by increases in high R&D-intensive 
sectors (33.8%) and medium-high sectors (26.3%).
• For the EU companies, the overall employment growth was 
19.0%, increasing by 35.1% in high R&D-intensive sectors, 
by 28.7% in medium-high and by 10.5% in low sectors.
• For the US companies, the overall employment growth 
(17.5 %) greatly varies by sector group: a strong increase 
for high R&D-intensive sectors (25.9 %) and a sharp 
decrease in low sectors (-23.8 %).
• For the Japanese companies, the overall employment 
increase of 15.8 % corresponded to an increase of 29.9 
% in medium-low R&D-intensive sectors and of 28.5 % in 
low sectors.
• The ratio of employment in high to medium-high R&D 
intensity sectors for companies based in Japan fell from 
37% to 33%, rose slightly for EU companies, from 38 % 
to 40%, and significantly increased for US companies from 
91 % to 100 %.  
It is important to remember that data reported by the 
Scoreboard companies do not inform about the actual 
geographic distribution of the number of employees. A 
detailed geographic analysis should take into account the 
location of subsidiaries of the parent Scoreboard companies 
(see analysis of the location of companies’ economic and 
innovation activities in chapter 5).
Figure 1.7 - R&D investment trends for the Scoreboard companies in the main world regions.
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Figure 1.8 - Employment trends by the Scoreboard companies for main world regions.
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This chapter describes the performance of individual 
companies, with a focus on the results of top R&D investors, 
highlighting those companies that show considerable 
changes in economic performance, in particular from an R&D 
viewpoint.
The world’s top 100 R&D companies are analysed, 
highlighting those presenting important changes from the 
previous year and those showing the best performance in 
terms of R&D and economic growth over the last 10 years. 
The group of top R&D investors includes major industrial 
players in key sectors such as IT hardware & software, 
pharmaceuticals and automobiles & parts. Key technological 
and market trends explain to a large extent changes observed 
in the Scoreboard indicators for these companies. Examples 
of such developments are illustrated in Box 2.1
The R&D ranking of the top 50 companies is presented in 
figure 2.1 and table 2.2 shows changes in such ranking since 
the first Scoreboard in 2004.
Key findings
• For the second consecutive year, the four top R&D 
investors remain the same: Volkswagen from Germany in 
the 1st place, Samsung Electronics from South Korea in 
the 2nd position, and Microsoft and Intel from the US in the 
3rd and 4th places.  The other companies in the top-ten are 
Novartis and Roche from Switzerland, Toyota from Japan, 
Google, Johnson & Johnson and Pfizer from the US.
• In 2014, among the top 100 companies, accounting for 
53.3% of the total R&D investment, 71 increased R&D 
investment (vs. 62 in 2013), including 35 companies with 
double-digit R&D growth; of the 29 that decreased R&D, 
6 decreased it by a double digit percentage. Regarding net 
sales, 71 companies reported an increase (vs. 68 in 2013), 
including 16 companies with double-digit sales growth.
• The top 100 group includes:
- 29 EU companies of which 20 have increased R&D (11 
by more than 10%), 
- 37 US companies of which 26 increased R&D (13 by 
more than 10%), 
- 16 from Japan of which 9 increased R&D (2 by more 
than 10%) and 
- 18 companies from other countries of which 16 
increased R&D (9 by more than 10%).
• The 5 companies showing the largest increase in R&D are 
Tata Motors, India (108.9 % - but most of this R&D is at its 
UK subsidiary, Jaguar Land Rover);  Facebook, US (88.4 %); 
Total, France (42.6 %); SK Hynix, South Korea (37.2 %) and 
Apple, US (35.0 %).  The 5 showing the largest decrease in 
R&D are Otsuka, Japan (-30.6%); Nokia, Finland (-21.4 %); 
Eli Lilly, US (-18.2 %); Finmeccanica, Italy (-14.6 %) and 
General Electric, US (-10.9 %).
• Among the top 100 group, since the beginning of the crisis 
in 2008, 21 companies have at least doubled their R&D 
investment (3 companies based in the EU, 10 from the US 
and 8 from other countries). This group of companies is 
mainly from high R&D-intensive sectors (13);  12 of them 
have increased net sales by more than 100% (7 from the 
US and 5 from other countries) and 7 companies increased 
employment by more than 100% (6 based in the US and 
1 from other non-EU countries). Many of these companies 
have made substantial acquisitions.
2.1 General trends
In the 2015 Scoreboard 123 companies have an R&D 
investment of more than € 1.0bn (37 from the EU and 47 
from the US) while 58 have R&D exceeding € 2.0bn (18 from 
the EU and 24 from the US).
The top 10 companies each invested more than €5.0bn in 
R&D and account for 14.7% of the total R&D investment by 
the 2500 Scoreboard companies.
The four top R&D investors are the same as in last year’s 
Scoreboard: In the 1st place the German company Volkswagen 
(€13.1bn), from South Korea in the 2nd position Samsung 
Electronics (€12.2bn) and from the US in the 3rd and 4th places 
Microsoft (€9.9bn) and Intel (€9.5bn).  The other companies 
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in the top-ten are from Switzerland Novartis (€8.2bn) and 
Roche (€7.4bn), from Japan Toyota Motor (€6.9bn), from the 
US Google (€8.1bn), Johnson & Johnson (€7.0bn), and Pfizer 
(€6.8bn).
The top 100 companies invested €323.4 billion, accounting 
for 53.3% of the total R&D investment and 28.5% of the 
total net sales by all the 2500 Scoreboard companies. The 
EU has 29 companies among the top 100 R&D investors, two 
companies less than it had in the 2014 Scoreboard. The US 
has 37 companies, two more than it had last year and Japan 
has 16, one company less than in last year’s Scoreboard. A 
new company from the rest of the world entered the group 
of top R&D investors (Tata Motors of India, jumping from 
place 104 to 49).
The EU companies in the top 100 are mainly from the 
Automobiles & Parts (7), Pharmaceuticals & Biotechnology 
(5) and ICT sectors (3). The US companies are mainly from 
the ICT (13), Pharmaceuticals & Biotechnology (10), and 
Chemicals (3) sectors. The Japanese companies operate 
mainly in the Automobiles & Parts (4) and Pharmaceuticals 
(4) sectors.
Seventy-one companies in the top 100 have shown positive 
R&D investment growth. Among them, 35 companies had 
double-digit R&D growth, and of these, 9 companies also 
showed double-digit growth in net sales.  
Most of the top 100 companies showing double-digit R&D 
increases are in the Pharmaceuticals & Biotechnology (10), 
ICT (9) and Automobiles & Parts (6) sectors. The companies 
showing the largest increase in R&D are Tata Motors, India 
(108.9 %);  Facebook, US (88.4 %); Total, France (42.6 %); SK 
Hynix, South Korea (37.2 %) and Apple, US (35.0 %).
Other companies among the top 100 group have shown 
double-digit growth in both R&D and net sales, e.g. 
Gilead Sciences, Biogen and eBay from the US; Taiwan 
Semiconductor (Taiwan) and Huawei from China.   
Twenty-nine companies in the top 100 have experienced a 
decrease in R&D investment. Among these, four companies 
decreased R&D investments and net sales by more than 
10 %.  The companies with the largest decrease in R&D are 
Otsuka, Japan (-30.6%); Nokia, Finland (-21.4 %); Eli Lilly, US 
(-18.2 %); Finmeccanica, Italy (-14.6 %) and General Electric, 
US (-10.9 %).
The R&D intensity of companies in the top 100, as in the 
previous year, increased slightly due to a higher R&D growth 
(6.4%) than net sales growth (2.5%). The EU and non-EU 
companies in the top 100 have the same average R&D 
intensity (6.3 %). 
Box 2.1 - Key technological trends concerning the top R&D investors.
Major technological trends can be classified into four groups:  
1.    ICT (information & communication technologies). These are IT hardware (e.g. more capable semiconductor 
chips following Moore’s Law), software & artificial intelligence and fast communications (optical and wireless). The 
internet-of-things (IoT) is just one example that uses all these three components of ICT.
2.    New materials and micro-electromechanical devices made from them. Examples are new battery materials, 
compound semiconductor devices, nanotechnology, graphene, advanced polymers (which are replacing metals in 
many applications), micro-sensors & actuators. Just one example of how nanotechnology is starting to affect our 
everyday lives are the nanocrystal/quantum dot ultra-high definition TV screens now being launched by companies 
such as Samsung and LG.
3.  Biotechnology and particularly therapeutic biotech is rapidly developing. Biotech includes genomics 
(genome sequencing, gene editing), monoclonal antibodies (the basis of many new drugs), drugs capable of fighting 
antibiotic-resistant infections, anti-viral drugs (for HIV, HepC etc.), regenerative medicine (stem cells etc.) and cancer 
immunotherapy. Biotech is also important outside medicine in areas such as improved animal/plant genetics and 
industrial biotech processes. The launch of Gilead Sciences’ 8-12 week cure for HepC was a major event of 2014.
4.  System advances include integration of the above three, for example advanced robotics (involving ICT & new 
materials), advanced implantable medical devices, driverless cars, additive manufacturing (3D printing) and renewable 
energy (such as highly efficient concentrated photovoltaic solar cells).
Out of the top 22 R&D companies in the 2015 Scoreboard, 15 are deeply involved in ICT or biotech with the other 
seven coming from the automotive sector. The increasing size of the R&D budgets of the fast-growing companies 
central to these key technologies are clearly apparent from some major changes apparent in the 2015 Scoreboard 
rankings. 
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These include ICT companies in online advertising and social media such as Google which is now #6 in the global 
ranking compared to #36 just four years ago, Facebook is #55 compared to #295 in 2011 and eBay is #59 compared 
to #114 in 2011. And in Biotech, Gilead Sciences is this year at #47 compared to #115 in 2011 with Celgene at #59 
vs. #113 in 2011.
We will take two examples of recent developments to illustrate the rapid progress that is being made – from system 
advances and biotech.
Google is using the cash from its dominant position in online advertising to develop new businesses such as advanced 
robotics (through its subsidiary Boston Dynamics), home automation/IoT (through NEST) and self-driving cars which 
it is already testing in substantial numbers on public roads. Apple also has a massive cash pile and is reported to 
be working on a self-driving car. These two ICT companies are now seen as a major potential threat by conventional 
automotive firms. Driverless cars are far from the only example where humans could be replaced by intelligent 
devices. Experts can foresee surgeonless operations using further development of robotic surgery systems such as 
Intuitive Surgical’s Da Vinci system (which currently has a surgeon at the ‘joystick’ controls and screen). Hundreds of 
Da Vinci systems have been installed in hospitals worldwide.
One of the major biotech events of early 2015 was the May 2015 ASCO conference (American Society of Clinical 
Oncology). The focus of interest at ASCO was cancer immunotherapy, the science of training the immune system to 
recognise and kill cancer cells. Immunotherapy drugs are now being approved to treat cancers like advanced melanoma 
and lung cancer. The leading company in this field is Bristol-Myers Squibb (with three approved immunotherapy 
treatments) followed by Merck (with two) but other companies such as AstraZeneca have several immunotherapy 
drugs in their pipelines. The next few years are likely to see many more immunotherapy drugs approved for use 
against an ever-widening range of cancers.
Source:  Innovomantex Ltd.
2.2 R&D changes driven by 
Mergers and Acquisitions 
(M&As) and Foreign Direct 
Investments (FDIs)
Changes in in-house company R&D are usually the results of 
organic growth or of the need to trim costs in difficult times. 
But in some cases big changes in R&D are the result of 
different corporate policies such as mergers & acquisitions 
(M&As) or demergers, when a company sharpens its focus by 
selling or spinning off one or more divisions, or investment in 
new assets (greenfield FDI).
For example, in the pharmaceutical sector, many companies 
access specialized R&D by acquiring smaller biotech 
companies via M&A to further diversify their portfolio of 
biopharmaceutical innovations or to acquire a promising 
pipeline drug (an example is the case of Gilead acquiring 
Pharmasset, a global leading US company engaged in anti-
viral and anti-cancer drugs). 
Automobile sector and technology hardware and electronic 
equipment sectors seem to engage more in greenfield FDI 
to benefit from local R&D resources. Often these projects 
involve the active participation of local companies. For 
instance, Huawei has opened an R&D centre in Spain, 
together with Telefonica to focus on fixed line and wireless 
communications equipment.
Both companies, Gilead and Huawei, have had outstanding 
R&D performance in the last few years.
Some figures concerning foreign direct investments (FDI) 
over the past 8 years (2007-2014) for the top 50 R&D 
investors are provided in Table 2.1. The table reports the 
total value of M&A deals, the number of cross-border M&A, 
the total number of M&A deals, the total value and number 
of greenfield FDI projects. 
Some of the companies do not report any M&A figures. 
In some cases, such as BMW, this is due to the business 
strategy of the company, in others, such as FIAT and Abbvie, 
this depends on a recent demerger (Abbvie, 2013) or from a 
recent merger (Fiat Chrysler, 2014). Although not available 
for all world top 50 R&D investors, the values of M&As are 
on average larger than those of greenfield FDI. There are 
also cases where companies agree to exchange assets and 
R&D programmes; a recent example was the deal between 
Novartis and GlaxoSmithKline over cancer drugs, consumer 
health products and vaccines.
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Table 2.1 – Merger and acquisition activities involving Scoreboard Companies.
Name
Tot value of 
M&A deals 
(€bn)
Cross 
border 
M&A
Tot 
n. of 
deals
Tot value 
of FDI 
(€bn)
N. FDI 
projects
PFIZER 64.89 4 19 0  
MERCK US 47.84 1 5 2.7 49
ROCHE 45.89 22 22 3.7 46
NOVARTIS 38.1 7 10 5.7 61
ORACLE 22.47 9 65 1 57
VOLKSWAGEN 20.71 3 12 43.3 266
GENERAL ELECTRIC 20.52 16 30 23.2 275
MICROSOFT 19.44 25 65 9.3 183
ASTRAZENECA 18.59 11 12 1.2 25
SANOFI-AVENTIS 18.46 14 17 3.8 54
GOOGLE 18.45 33 122 6.2 97
JOHNSON & JOHNSON 18.32 3 11 1.9 54
HEWLETT-PACKARD 17.25 10 39 7.1 171
CISCO SYSTEMS 16.07 12 56 5.6 75
SIEMENS 15.64 32 39 14.5 252
GLAXOSMITHKLINE 14.91 15 17 3.3 62
TAKEDA PHARMACEUTICAL 13.49 4 5 0.7 30
ELI LILLY 12.86 2 10 1.9 21
BAYER 12.44 2 5 4 124
IBM 11.37 26 79 10.1 383
BRISTOL-MYERS SQUIBB 10.94 0 7 1.2 12
HITACHI 10.88 8 27 10.2 143
GILEAD SCIENCES 10.63 0 7 0.2 10
AMGEN 10.58 4 10 0.5 9
PANASONIC 10.46 7 25 4.1 96
INTEL 8.06 18 37 8.2 69
NOKIA 6.97 16 19 2.2 87
ROBERT BOSCH 5.69 14 32 7.5 191
SAP 5.54 24 30 1.4 71
ERICSSON 4.68 31 33 3 72
GENERAL MOTORS 4.16 1 3 32.3 158
APPLE 4.08 12 35 0.3 20
SONY 3.34 2 14 4.3 86
QUALCOMM 2.94 8 22 2.2 23
EMC 2.25 6 34 1.4 61
TATA MOTORS 1.54 3 5 1 13
TOYOTA MOTOR 1.3 2 7 26.9 282
SAMSUNG ELECTRONICS 1.19 12 24 16.3 59
DAIMLER 0.47 4 14 22.2 139
FORD MOTOR 0.23 9 10 26.1 120
HONDA MOTOR 0.21 3 7 1.2 8
LG ELECTRONICS 0.16 1 6 1.8 52
NISSAN MOTOR 0.13 1 2 1.9 11
DENSO 0.01 2 2 1.7 60
FIAT CHRYSLER AUTOMOBILES 0 1 1 27.1 160
AIRBUS 0 1 1 9.8 167
HUAWEI INVESTEMENT & HOLDING CO    5.6 131
BMW    10.2 80
ABBVIE    0.3 4
BOEHRINGER INGELHEIM    1 28
Source: Zephir database, Bureau van Dijk and fDi Markets database, the Financial Times.
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2.3 Long-term performance of 
top R&D companies
This section analyses the behaviour of the top companies 
over the last 10 years based on our history database 
containing company data for the period 2002-2013.  Results 
of companies showing outstanding R&D and economic 
results are underlined. 
Ranking of the top 50
Table 2.2 shows the evolution of the R&D rankings of the 
top 50 companies since the first Scoreboard in 2004 and 
the most important changes are highlighted. It is important 
to note, as stated in the previous section and in past reports, 
that the growth of companies is often accompanied by 
mergers and acquisitions. 
There are 15 EU companies (18 in 2004) and 35 non-EU 
companies (32 in 2004). 
In the EU group, six companies left the top 50 (Alcatel, Istituto 
Finanziario Industriale, Philips, Renault, BAE Systems and 
Peugeot) and three companies joined the top 50 (Boehringer 
Ingelheim, Fiat Chrysler and SAP).
In the non-EU group, eleven companies left the top 50 (Fujitsu, 
Canon, Fujitsu, Matsushita Electric, NEC, NTT, Motorola, 
Nortel Networks, Wyeth, Delphi and Sun Microsystems) and 
fourteen companies joined the top 50 (AbbVie, Amgen, Apple, 
Denso, EMC, Gilead Sciences, Google, Huawei, LG Electronics, 
Oracle, Panasonic, Qualcomm, Takeda Pharmaceuticals and 
Tata Motors).
The distribution of the top 50 companies by main industrial 
sector and region changed from 2004 to 2014 as follows:
• Automobiles & Parts, from 13 (EU 7) to 12 (EU 5)
• Pharma & Biotech, from 11 (EU 3) to 16 (EU 5)
• ICT industries, stable at 13 (EU 3)
The EU companies that improved by at least 20 places are 
Bayer (now ranked 29th) and SAP (now 50th).  
There are 9 non-EU companies that gained more than 20 
places. They include Google, (now 6th), Samsung Electronics 
(now 2nd), Huawei (now 15th), Apple (now 18th), Oracle (now 
22nd) Qualcomm (now 23rd), EMC (now 39th), Takeda (now 
45th), LG Electronics (now 46th), Gilead Sciences (now 48th) 
and Tata Motors (now 49th)8. These examples illustrate 
the big advances made in this ten year period in software/
internet and biotechnology.
Three companies dropped twenty or more places but 
remained within the top 50: Sony (now 37th), Panasonic (now 
38th) and Nokia (now 41st). 
8 Amazon could be in the top 20 companies by R&D but it does 
not separate R&D and content sufficiently in its annual report to 
enable the overall R&D figure to be reliably extracted. The only R&D 
included in the listing is therefore that which was capitalised rather 
than expensed.
T h e  2 0 1 5  E U  I n d u s t r i a l  R & D  I n v e s t m e n t  S c o r e b o a r d
38
Figure 2.1.  The world’s top 50 companies by their total R&D investment (€m) in the 2014 Scoreboard.
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50.	  SAP,	  Germany	  
49.	  TATA	  MOTORS,	  India	  
48.	  GILEAD	  SCIENCES,	  US	  
47.	  TOSHIBA,	  Japan	  
46.	  LG	  ELECTRONICS,	  South	  Korea	  
45.	  TAKEDA,	  Japan	  
44.	  BOEHRINGER	  INGELHEIM,	  Germany	  
43.	  DENSO,	  Japan	  
42.	  ABBVIE,	  US	  
41.	  NOKIA,	  Finland	  
40.	  HEWLETT-­‐PACKARD,	  US	  
39.	  EMC,	  US	  
38.	  PANASONIC,	  Japan	  
37.	  SONY,	  Japan	  
36.	  ELI	  LILLY,	  US	  
35.	  BRISTOL-­‐MYERS	  SQUIBB,	  US	  
34.	  NISSAN	  MOTOR,	  Japan	  
33.	  GENERAL	  ELECTRIC,	  US	  
32.	  AMGEN,	  US	  
31.	  AIRBUS,	  The	  Netherlands	  
30.	  FIAT	  CHRYSLER,	  The	  Netherlands	  
29.	  BAYER,	  Germany	  
28.	  ERICSSON,	  Sweden	  
27.	  GLAXOSMITHKLINE,	  UK	  
26.	  ASTRAZENECA,	  UK	  
25.	  IBM,	  US	  
24.	  SIEMENS,	  Germany	  
23.	  QUALCOMM,	  US	  
22.	  ORACLE,	  US	  
21.	  BMW,	  Germany	  
20.	  HONDA	  MOTOR,	  Japan	  
19.	  SANOFI-­‐AVENTIS,	  France	  
18.	  APPLE,	  US	  
17.	  ROBERT	  BOSCH,	  Germany	  
16.	  CISCO	  SYSTEMS,	  US	  
15.	  HUAWEI,	  China	  
14.	  DAIMLER,	  Germany	  
13.	  FORD	  MOTOR,	  US	  
12.	  MERCK	  US,	  US	  
11.	  GENERAL	  MOTORS,	  US	  
10.	  PFIZER,	  US	  
9.	  TOYOTA	  MOTOR,	  Japan	  
8.	  JOHNSON	  &	  JOHNSON,	  US	  
7.	  ROCHE,	  Switzerland	  
6.	  GOOGLE,	  US	  
5.	  NOVARTIS,	  Switzerland	  
4.	  INTEL,	  US	  
3.	  MICROSOFT,	  US	  
2.	  SAMSUNG,	  South	  Korea	  
1.	  VOLKSWAGEN,	  Germany	  
R&D	  investment	  (Euro	  million)	  
USA	  
EU	  
Japan	  
South Korea	  
Switzerland	  
China	  
India	  
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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Table 2.2 – The top 50 companies in 2015 Scoreboard: R&D data and rank change 2004-2015.
Rank in 
2015 Company Country
R&D in 
2014 (€m)
R&D 
intensity (%)
Rank change 
2004-2015
1 VOLKSWAGEN Germany 13120.0 6.5 up 7
2 SAMSUNG South Korea 12187.0 7.9 up 31
3 MICROSOFT US 9921.7 12.9 up 10
4 INTEL US 9502.5 20.6 up 10
5 NOVARTIS Switzerland 8217.6 16.7 up 15
6 GOOGLE US 8098.2 14.9 up > 200 
7 ROCHE Switzerland 7422.1 18.8 up 11
8 JOHNSON & JOHNSON US 6996.1 11.4 up 4
9 TOYOTA MOTOR Japan 6858.4 3.7 down 4
10 PFIZER US 6844.6 16.8 down 8
11 GENERAL MOTORS US 6095.0 4.7 down 5
12 MERCK US US 6056.3 17.4 up 17
13 FORD MOTOR US 5683.2 4.8 down 12
14 DAIMLER Germany 5650.0 4.4 down 11
15 HUAWEI China 5441.2 14.0 up > 200 
16 CISCO SYSTEMS US 5112.4 12.6 up 14
17 ROBERT BOSCH Germany 5042.0 10.3 up 10
18 APPLE US 4975.7 3.3 up 86
19 SANOFI-AVENTIS France 4812.0 14.2 down 3
20 HONDA MOTOR Japan 4576.6 5.0 down 9
21 BMW Germany 4566.0 5.7 up8
22 ORACLE US 4549.9 14.5 up 24
23 QUALCOMM US 4511.2 20.7 up 69
24 SIEMENS Germany 4377.0 6.1 down 19
25 IBM US 4335.7 5.7 down 15
26 ASTRAZENECA UK 4164.4 19.4 down 1
27 GLAXOSMITHKLINE UK 4002.0 13.5 down 16
28 ERICSSON Sweden 3856.7 15.9 down 11
29 BAYER Germany 3689.0 8.7 up 31
30 FIAT CHRYSLER The Netherlands 3665.0 3.8 new
31 AIRBUS The Netherlands 3616.0 6.0 up 4
32 AMGEN US 3498.9 21.2 up 5
33 GENERAL ELECTRIC US 3486.5 2.8 up 4
34 NISSAN MOTOR Japan 3455.7 4.4 unchanged
35 BRISTOL-MYERS SQUIBB US 3426.4 26.2 up 7
36 ELI LILLY US 3249.5 20.1 up 5
37 SONY Japan 3170.1 5.7 down 22
38 PANASONIC Japan 3121.8 5.9 down 31
39 EMC US 2915.7 14.5 up 21
40 HEWLETT-PACKARD US 2839.1 3.1 down 17
41 NOKIA Finland 2718.0 17.9 down 31
42 ABBVIE US 2715.6 16.5 new
43 DENSO Japan 2699.4 9.2 down 8
44 BOEHRINGER INGELHEIM Germany 2654.0 19.9 up 18
45 TAKEDA Japan 2608.7 21.5 up 28
46 LG ELECTRONICS South Korea 2596.9 5.9 up 64
47 TOSHIBA Japan 2407.9 5.3 down 17
48 GILEAD SCIENCES US 2350.7 11.5 up 318
49 TATA MOTORS India 2345.5 6.9 new
50 SAP Germany 2307.0 13.1 up 20
Note: companies in “blue” went up more than 20 ranks and in “red” lost more than 20 ranks  
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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High R&D performance among the top 100
Since the beginning of the crisis in 2008, many companies 
among the top 100 group have shown outstanding 
performance: Twenty-one companies have at least doubled 
their R&D investment (3 of them based in the EU, 10 from 
the US and 8 from other countries). This group of companies 
is drawn mainly from high R&D-intensive sectors (12) and 
from medium-high R&D intensive sectors (5).   Twelve out 
of the 22 companies have increased net sales by more than 
100% (7 from the US and 5 from other countries) and seven 
companies increased employment by more than 100% (6 
based in the US and 1 from other non-EU countries). Many of 
these companies have made substantial acquisitions.
Since 2010, when companies from most regions started to 
recover from the crisis (see chapter 1), many companies 
among the top 100 group have accelerated their R&D 
investments. The table 2.3 presents the list of 14 companies 
that increased R&D investment by more than 100% in the 
period 2010-2014 (3 based in the EU, 8 from the US and 3 
from other countries). As mentioned above, many companies’ 
large increases in R&D are driven by acquisitions.
Table 2.3 -  Companies among the top 100 R&D investors that showed the largest R&D investment growth 
since 2010.
World 
rank Company Country Sector (ICB 3-d)
R&D in 
2014 
(€bn.)
R&D 
int. 
(%)
R&D 
growth 
2010-2014 
(%)
49 TATA MOTORS IN Automobiles & Parts 2.3 6.9 859.9
91 CHINA RAILWAY CN Construction & Materials 1.3 1.6 365.0
55 FACEBOOK US Software & Computer Services 2.2 21.4 359.7
18 APPLE US Technology Hardware & Equipment 5.0 3.3 239.0
48 GILEAD SCIENCES US Pharmaceuticals & Biotechnology 2.4 11.5 205.7
6 GOOGLE US Software & Computer Services 8.1 14.9 161.4
90 SAFRAN FR Aerospace & Defence 1.3 8.7 155.9
86 WESTERN DIGITAL US Technology Hardware & Equipment 1.4 11.3 134.1
30 FIAT CHRYSLER NL Automobiles & Parts 3.7 3.8 118.2
59 EBAY US General Retailers 2.0 13.4 117.4
23 QUALCOMM US Technology Hardware & Equipment 4.5 20.7 114.9
1 VOLKSWAGEN DE Automobiles & Parts 13.1 6.5 109.7
76 BOMBARDIER CA Aerospace & Defence 1.5 9.1 106.4
62 CELGENE US Pharmaceuticals & Biotechnology 1.9 30.0 105.9
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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High R&D intensive companies among the top 100
There are 42 companies out of the top 100 that invested 
in R&D more than 10% of their net sales. These companies 
are mostly from Pharmaceuticals & Biotechnology (22) and 
ICT sectors (16). Twenty-two of them are based in the US 
and thirteen in the EU. It is interesting to note that 80% of 
these high R&D-intensive companies also have double-digit 
profitability.
This group of companies includes US leading companies in 
biotechnology (Celgene, Amgen, Biogen, Gilead, and Bristol-
Myers Squibb) and fast growing software/internet companies 
(Facebook, Google and Oracle). These companies have 
succeeded in exploiting new technologies and some of them 
are exploiting their cash piles to engage in new technological 
areas, e.g. Google expansion in self-driving cars, advanced 
robotics and automation including internet-of-things.
The EU companies in this group are also mostly from the 
Pharmaceuticals & Biotechnology sector (7 out of 13). A 
successful company in this group is the Danish company 
Novo Nordisk, which is the world leader in treatments for 
diabetes, the world’s fastest growing major disease, with 
around 50% global market share. A company demerged 
from Novo Nordisk in 2000, Novozymes (now ranked #43 in 
the Scoreboard), is the world leader in industrial enzymes for 
household products, biofuels and bioenergy.
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This chapter presents the main R&D trends among the 2015 
Scoreboard companies aggregated by industrial sectors9. 
It comprises the ranking of sectors by their level of R&D 
investment, R&D intensities, rates of R&D growth and the 
comparison of such trends across world regions. 
Key findings
• Companies from the Software & Computer Services 
showed the highest R&D growth (12.8%). This sector is 
dominated by the US companies which account for 77% 
of the total world R&D and increased it by 13.1% in 2014. 
Large companies such as Facebook and Google showed 
big changes in their R&D investments (88.4% and 24.3% 
respectively). Also many software companies from China 
showed double digit R&D growth, e.g. Baidu (69.9%) and 
Tencent (52.2%).  
• The top two R&D investing sectors achieved an increase 
of R&D above the world average (6.8%), Pharmaceuticals 
& Biotechnology (7.2%) and Automobile & Parts (9.9%). 
Other sectors that achieved a fair increase on R&D were 
Technology Hardware & Equipment (6.7%) and Health 
Care Equipment & Services (8.7%). Among the large R&D 
sectors, those showing a poor performance were Industrial 
Engineering (2.0%), Chemicals (1.9%) and Aerospace & 
Defence (1.5%).           
• In the Pharmaceuticals & Biotechnology sector, 
companies operating in biotechnology increased R&D 
by 21.3% whereas the traditional pharmaceutical 
companies increased it only by 4.8%.  As observed in the 
previous edition, this is due to the rapid development of 
biotechnology, illustrated by an outstanding performance 
by the top biotechnology companies mostly based in the 
US.  
• Among the top 5 sectors, companies based in the EU had 
the highest R&D growth in Automobile & Parts (7.9 %) 
and Pharmaceuticals & Biotechnology (6.5 %). The highest 
9 According to the Industry Classification Benchmark (ICB) applied in the Scoreboard.
R&D growth in the EU was showed by the Health Care 
Equipment & Services sector (8.0%). 
• Trends observed in the Scoreboard over the last 10 
years show characteristic but very different industrial 
specialisations by the EU and US companies. This difference 
persisted after the financial crisis and appears to have 
been reinforced over the past few years:
- Concentration of the EU companies in medium-high R&D 
intensity sectors (total domestic and sector world R&D 
shares of 44.6% and 33.8% respectively).  In particular 
in Automobiles & Parts with domestic and world R&D 
shares of 26.2 % and 47.3 % respectively.  
- Dominance of US companies in high R&D-intensity 
sectors (total domestic and sector world R&D shares of 
74.2% and 54.7% respectively) and particularly in ICT 
industries and biotechnology.  The US companies in ICT 
have domestic and sector world R&D shares of 45.8% 
and 67.1% respectively.
• A detailed analysis of the health and ICT sectors shows 
a significant gap for the EU vis-à-vis the US in terms of 
number of companies, R&D investment and R&D intensity. 
However, the Scoreboard also shows a number of world-
beating EU companies of substantial size in these sectors, 
e.g. Novo Nordisk, ASML and ARM all invest heavily in R&D 
and dominate their world market niches. The gap is due to 
the fact that there are too few of them.   
3.1 General R&D trends
Figure 3.1 shows the R&D rankings of companies from the 
main industrial sectors including the relative R&D share 
by main world region. The specialisation of the main world 
regions, represented by the share of sectors within the 
regions’ total R&D investment, is given in figure 3.2.
• R&D investment in the Scoreboard remains highly 
concentrated by sector: Out of 41 industrial sectors, the 
top three –Pharmaceuticals & Biotechnology, Technology 
Hardware & Equipment and Automobiles & Parts– account 
3  R&D distribution by industrial 
sector
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for 49.4% of the total R&D investment by the Scoreboard 
companies; the top 6 and top 15 sectors constitute, 
respectively, 67.4 % and 91.5% of the total R&D in the 
Scoreboard. A similar concentration of R&D in a relatively 
small number of industrial sectors has been observed over 
the last 12 years.
• The ranking of the top 11 sectors has changed as follows: 
The Automobiles & Parts sector took over the 2nd position 
from the Technology Hardware & Equipment (now 3rd).
• The Pharmaceuticals & Biotechnology sector is in the 
first position in the R&D ranking, maintaining a similar 
share of the total R&D investment (18.2%). It is followed 
by the Automobile & Parts and Technology Hardware & 
Equipment sectors with a similar share of R&D, 15.6%. 
• The R&D specialisation (share of R&D investment) of the 
main regions in the top 3 sectors are: 
- In the EU, Automobiles & Parts (26.3 %), Pharmaceuticals 
& Biotechnology (18.4 %), and Technology Hardware & 
Equipment (8.8 %); 
- In the US, Technology Hardware & Equipment (24.7 %), 
Pharmaceuticals & Biotechnology (21.2 %) and Software 
& Computer Services (21.0 %);
- In Japan, Automobiles & Parts (28.6%), Electronic & 
Electrical Equipment (13.0%) and Pharmaceuticals & 
Biotechnology (10.7%). 
• The contribution to the total Scoreboard R&D:
 - by EU companies is 48.6 % to Aerospace & Defence, 
47.4% to Automobiles & Parts and 35.4% to the 
Industrial Engineering sectors; 
- the US contributes 75.0% to Software and Computer 
Services, 63.7% to Health Care Equipment & Services 
and 55.6% to Technology Hardware & Equipment and; 
- Japan contributes 60.7 % to Leisure Goods, 29.1 % to 
General Industrials, 28.1% to Chemicals and 26.0 % to 
Automobiles & Parts.
3.2 R&D growth by industrial 
sector
The actual contribution of an industrial sector to the overall 
R&D growth of a region depends on its rate of R&D change 
and the sector’s share of total R&D of the region. Figures 
3.1 and 3.2 show the shares of the main industrial sectors 
and table 3.1 shows their ranking by R&D annual growth 
rate worldwide for the Scoreboard companies based in the 
main world regions (EU-608, US-829, and Japan-360, RoW 
group-703).
The following points are observed for the top 11 sectors 
accounting for 85.4% of the total R&D investment of the 
Scoreboard companies:
• Worldwide, the Software & Computer Services sector 
shows the highest one-year growth rate (12.8%) followed 
by Automobiles & Parts (9.9%) and Health Care Equipment 
& Services (8.7%) sectors. The significant R&D growth rate 
of the Software & Computer Services sector is due to a 
large extent by the R&D growth of US companies such 
as Facebook (88.4%) and Google (24.3%). Many Chinese 
companies showed double digit R&D growth, e.g. Baidu 
(69.9%) but with Chinese software R&D significantly less 
than 10% of US R&D in this sector. 
• Among the companies based in the EU, Health Care 
Equipment & Services sector shows the highest one-
year growth rate (8.0%), followed by the Automobiles & 
Parts (7.9%). The sectors showing the lowest one-year 
R&D growth are Leisure Goods (-4.9%) and Industrial 
Engineering (-4.1%).  The significant R&D growth of 
the Automobiles & Parts sectors is mostly due to large 
companies that increased R&D above the sector’s average 
rate, e.g. Peugeot (14.9 %), Continental (14.4 %), and 
Mahle (64.3 %). 
• Among the companies based in the US, the Software & 
Computer Services sector shows the highest one-year 
growth rate (13.1%) followed by Pharmaceuticals & 
Biotechnology (10.7%). Sectors showing the lowest one-
year R&D growth are General Industrials (-2.5 %) and 
Industrial Engineering (0.8%). 
• For Japanese companies, the highest one-year growth rate 
is shown by Industrial Engineering (12.4%). The poorest 
performance was shown by Software & Computer Services 
(-5.7%) and Leisure Goods (-2.9%).
• The companies from the RoW group had impressive R&D 
growth rates in Automobiles & Parts (39.6%) and Software 
& Computer Services (34.4%). The Automobiles & Parts 
sector in this group is led by a few large companies that 
showed a high R&D increase, for example, Tata Motors 
(108.9%), Hyundai (26.9%) and Saic Motor (16.0%). 
The highest R&D growth companies in the Software & 
Computer Services were Chinese companies, e.g. Baidu 
(69.9%), Tencent (52.2%) and Qihoo 360 Technology 
(59.2%). However, almost half of the total Chinese R&D 
comes from the ‘other sectors’ group – a much higher 
proportion than for the other major country/regional 
groupings (as shown in Fig. 3.1).
Apart from the top industries, there were important R&D 
changes in some other sectors:
• Most services sectors showed double-digit R&D growth, 
e.g. Financial Services (22.2%), Travel & Leisure (22.6 %) 
and General Retailers (15.1 %).
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• As observed in the past three years, the alternative 
energy sector that showed a substantial increase of R&D 
investment before the crisis, continued to decrease R&D 
investment in 2014 though at a lower pace (-1.1 %), 
compared with (-1.9 %) in the previous period and the 
sharp R&D reduction in 2012 (-22.9%).
• In 2014, the Industrial Transportation sector reversed the 
negative trend of the past years, increasing significantly 
R&D (13.8 %).
Figure 3.1 - R&D ranking of industrial sectors and regional shares for the world’s top 2500 companies.
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Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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Figure 3.2 - R&D shares of sectors of the main world regions.
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3.3 R&D intensity by sector
Table 3.2 provides the list of the main industrial sectors 
ranked by worldwide R&D intensity for the 2500 Scoreboard 
companies grouped by main world region. 
The following points are observed:
• Some industrial sectors increased their R&D intensity as 
R&D investment increased more than net sales in 2014, in 
particular the Automobiles & Parts sector (9.9% vs. 5.9%). 
The opposite happened for Leisure Goods (1.0 % vs. 3.3%) 
and Health Care Equipment & Services (8.7% vs. 17.5%).
• Four sectors have an R&D intensity of more than 5.0%: 
Pharmaceuticals & Biotechnology, the IT sectors (Software 
& Computer Services and Technology Hardware & 
Equipment) and Leisure Goods (mainly electronic leisure). 
The sector with the lowest R&D intensity is Oil & Gas 
Producers (0.3%). 
• Among the top 11 sectors, the R&D intensity of EU 
companies is larger than that of the US and Japan in 6 
sectors (Electronic & Electrical Equipment, Technology 
Hardware & Equipment, Industrial Engineering, General 
Industrials, Automobiles & Parts and Aerospace & 
Defence). Japanese companies show higher R&D intensity 
than the EU and the US in sectors such as Health Care 
Equipment & Services and Chemicals. The R&D intensity 
of US companies is higher than that of the EU and Japan 
in Pharmaceuticals & Biotechnology and Software & 
Computer Services.
• As observed in previous Scoreboards, the overall lower 
average of R&D intensity of the EU companies is due to 
their large share of low R&D-intensive sectors with very 
large sales such as Oil & Gas, Mining, Banks, as compared 
to a similar group of non-EU companies. Conversely, the 
high average  R&D intensity of the US companies is due 
to their considerable weight in high R&D-intensive sectors 
(see Figures 3.1 and 3.2)
Table 3.1 - Ranking of top 11 industrial sectors by overall one-year R&D growth in the 2015 Scoreboard.
Sector Global R&D change (%) 
EU-608 
R&D
US-829 
R&D
Japan-360 
R&D
RoW-703 
R&D
Software & Computer Services 12.8 4.6 13.1 -5.7 34.4
Automobiles & Parts 9.9 7.9 6.3 6.6 39.6
Health Care Equipment & Services 8.7 8.0 8.7 7.4 14.3
Pharmaceuticals & Biotechnology 7.2 6.5 10.7 -1.0 4.2
Technology Hardware & Equipment 6.7 -1.7 7.0 1.3 16.7
Electronic & Electrical Equipment 6.1 2.0 4.9 2.1 11.0
Industrial Engineering 2.0 -4.1 0.8 12.4 8.3
Chemicals 1.9 -0.8 1.3 3.3 4.7
General Industrials 1.5 -2.1 -2.5 5.4 14.4
Aerospace & Defence 1.5 1.2 3.4 20.6 -2.7
Leisure Goods 1.0 -4.9 8.0 -2.9 8.2
Top 11 industries 7.1 4.0 8.3 3.0 13.2
Rest of 30 5.1 0.5 6.1 -1.0 12.9
All 41 industries 6.8 3.3 8.1 2.6 13.1
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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3.4 Growth of net sales and 
profitability level by industrial 
sector
Table 3.3 shows the ranking of the top 11 industrial sectors, 
accounting for 85.4% of the total R&D and 50.8% of the 
total net sales, by overall one-year growth of net sales for 
the companies based in the EU, the US, Japan and the RoW 
group. 
The following points are observed:
• Worldwide, the Health Care Equipment & Services sector 
shows the highest one-year growth rate of net sales 
(17.5%) led mainly by Mckesson (US), largest sector’s 
company by sales and, to a lesser extent, by  Thermo 
Fisher Scientific (US), Fresenius (Germany) and Medtronic 
(Ireland) 10. The following sectors by growth rate on 
sales were Software & Computer Services (9.5%) and 
Automobiles & Parts (5.9%). 
10 Headquartered in Ireland but with operational centre in the US.
• Among the companies based in the EU, the highest growth 
rates of net sales are in Health Care Equipment & Services 
(10.7%) and Leisure Goods (7.6 %). The sector showing 
the lowest one-year sales growth is General Industrials 
(-6.7%). Among the largest sectors in the EU, the highest 
profitability is shown in Software & Computer Services 
(17.3 %) followed by Pharmaceuticals & Biotechnology 
and Health Care Equipment & Services (14.7 %). The EU 
companies’ lowest profitability is in the Oil & Gas Producers 
sector (5.2 %). 
• Among the companies based in the US, the Health Care 
Equipment & Services sector shows for the second 
consecutive year the highest one-year growth rate for sales 
(20.5%) followed by Software & Computer Services (6.6%). 
The sector showing the lowest one-year R&D growth is 
Automobiles & Parts (1.2 %).  The US-based companies 
have the highest profitability in Pharmaceuticals & 
Biotechnology (24.4 %) and Software & Computer Services 
(21.7 %). The US companies’ lowest profitability is in the 
Automobiles & Parts sector (3.6 %). 
• For Japanese companies, the highest one-year growth 
rate for sales is shown by the relatively small sector of 
Software & Computer Services (12.4%) and by Industrial 
Table 3.2 - Ranking of the top 11 industrial sectors by overall R&D in the 2015 Scoreboard.
Sector
Global R&D 
intensity 
(%)
EU-608 
R&D 
intensity 
(%)
US-829 
R&D 
intensity 
(%)
Japan-360 
R&D intensity 
(%)
RoW-
703 R&D 
intensity (%)
Pharmaceuticals & Biotechnology 14.4 13.3 17.1 13.3 12.0
Software & Computer Services 10.1 10.6 13.2 2.1 6.8
Technology Hardware & Equipment 8.0 15.1 9.9 5.2 4.2
Leisure Goods 5.8 3.0 5.8 5.8 6.2
Aerospace & Defence 4.5 6.0 3.2 1.4 6.0
Electronic & Electrical Equipment 4.5 5.2 4.0 4.4 4.3
Automobiles & Parts 4.4 5.5 4.0 4.1 2.7
Health Care Equipment & Services 3.8 5.0 3.1 6.9 9.9
Industrial Engineering 2.9 3.2 2.9 2.8 2.6
Chemicals 2.6 2.1 3.4 3.6 1.7
General Industrials 2.5 4.2 2.7 2.9 1.1
Top 11 industries 5.7 6.2 7.2 4.3 4.1
Rest of 30 1.0 0.8 1.3 1.1 1.0
All 41 industries 3.4 2.8 5.2 3.3 2.4
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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Engineering (10.9%). The poorest performance is shown by 
Pharmaceuticals & Biotechnology (-2.4%). The profitability 
of companies based in Japan is generally lower than their 
counterparts in the EU and the US, for example 10.2 % for 
Pharmaceuticals & Biotechnology. The highest profitability 
sector for Japanese companies is Health Care Equipment 
& Services (11.8 %). 
• The companies based in the RoW group showed the highest 
increase in net sales in Software & Computer Services 
(22.4%) which also shows the highest profitability (23.2%).
Table 3.3 - Ranking of top 11 industrial sectors by overall one-year net sales growth in the 2015 Scoreboard.
Sector
Overall 
sales 
change (%)
EU-608 
Sales 
change (%)
US-829 
Sales 
change (%)
Japan-360 
Sales change 
(%)
RoW-703 
Sales change 
(%)
Health Care Equipment & Services  17.5 10.7 20.5 7.9 11.9
Software & Computer Services 9.5 6.5 6.6 12.4 22.4
Automobiles & Parts 5.9 5.6 1.2 7.9 8.6
Technology Hardware & Equipment 4.8 -6.5 6.2 4.7 6.2
Pharmaceuticals & Biotechnology 4.6 3.4 6.5 -2.4 6.5
Aerospace & Defence 4.2 1.8 3.8 11.0 16.5
Leisure Goods 3.3 7.6 1.6 2.5 5.4
Industrial Engineering 2.3 1.6 1.5 10.9 -0.4
Electronic & Electrical Equipment 2.0 -0.7 3.2 5.0 1.0
Chemicals 1.0 0.3 2.8 5.1 -2.9
General Industrials 0.3 -6.7 2.0 3.5 -1.9
Top 11 industries 4.5 2.6 5.3 6.1 3.9
Rest of 30 -0.1 -2.9 0.3 0.8 3.6
All 41 industries 2.2 -1.0 3.6 4.3 3.7
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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3.5 Changes in indicators by 
region and sector groups
It is interesting to see the distribution of R&D investment 
of the Scoreboard companies across regions and sectors 
using an aggregation of the 41 industrial sectors into four 
groups of high-, medium-high-, medium-low- and low- R&D 
intensity (see definitions in Box 1.2 in chapter 1).
It is interesting to compare the distribution of the R&D 
investment grouped into sectors between regions (world 
distribution showing the weight of each region in each 
sector) and within regions (domestic distribution showing the 
region’s sector specialisation). 
The R&D investment grouped into sectors can be distributed 
across regions (world distribution) to show the region’s 
weight per sector and within regions (domestic distribution) 
to show the region’s sector specialisation. As shown in 
Table 3.4, the world and domestic distribution of the R&D 
investment shows clear differences by world region:
• Companies based in the EU specialise in medium-high 
R&D-intensive sectors (44.6% of total R&D of the EU 
companies) and contribute 33.8% of the total world 
R&D of that sector group. Industrial sectors accounting 
for a large share of total world R&D of these sectors 
are Automobiles & Parts (47.5%), Aerospace & Defence 
(48.5%) and Industrial Engineering (35.4%). 
• Those based in the US specialise in high R&D intensive 
sectors (74.2% of total R&D of the US companies) and 
contribute 54.7% of the world R&D of that sector group. 
Industrial sectors accounting for a large share of total 
world R&D of these sectors are Software & Computer 
Services (77.0%), Technology Hardware & Equipment 
(60.7%) and Health Care Equipment & Services (59.7%). 
The R&D share of US companies is also larger than that of 
the other regions in the Pharmaceuticals & Biotechnology 
sector (44.7%) and much larger in the Biotechnology sub-
sector (88.0%).  
• Japanese companies specialise in medium-high R&D 
intensive sectors (61.5% of total domestic R&D) while 
contributing 23.7% of the world R&D of that sector group. 
The industrial sectors with highest weight in the total world 
R&D are Leisure Goods (60.7 %), General Industrials (29.1 
%) and Chemicals (28.1 %).
• Chinese companies specialise in medium-high and low 
R&D-intensive sectors (45.1% and 25.7% respectively) 
and contribute 23.3% of the world R&D in the low sectors.
• Companies based in other countries (mainly Switzerland, 
South Korea and Taiwan) specialise in high and medium-
high R&D-intensive sectors (48% and 40% respectively) 
and contribute 16.4% of the world R&D in the low sectors.
Table 3.4 -  World and domestic R&D distribution of the 2500 Scoreboard companies by sector groups for the 
main regions.
 Sector 
 High                      Share (%)
Medium-high 
Share (%)
Medium-low Share 
(%)
Low                 
Share (%)
Region’s 
world                  
Share (%)  
Region world   domestic   world   domestic   world   domestic   world   domestic    
EU 21.2 39.1 33.8 44.6 37.1 6.0 44.3 10.3 28.1
US 54.7 74.2 20.8 20.2 35.4 4.2 8.4 1.4 38.2
Japan 8.5 30.7 23.7 61.5 13.4 4.2 7.7 3.5 14.3
RoW 15.6 41.7 21.7 41.5 14.1 3.3 39.7 13.5 19.4
Note: Sector groups as defined in Box 1.1 
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD. 
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3.6 Comparison of the EU and 
US companies in health and ICT 
industries  
This section describes the main characteristics of the 
samples of companies based in the EU and the US for high 
R&D-intensive industries that are important from R&D and 
economic perspectives.  R&D plays an important role for the 
competitiveness of these industries and they have a role as 
enablers for the whole value-chain of key sectors ranging 
from ICT-related industries, transport and health. 
Moreover, EU based companies compared with their main 
US counterparts present a weak structural position both in 
terms of number and weight of companies in most of these 
industries. As observed in previous Scoreboard editions, 
the EU gap in these industries is particularly sizeable and 
widening against the US companies. In fact trends observed 
over the past 10 years show a growing dominance of 
US companies in sectors such as Software/Internet and 
Biotechnology where a number of larger key companies are 
rapidly moving up the R&D rankings (as shown in chapter 2). 
Table 3.5 describes the main characteristics of the companies 
based in the EU and the US in three sub-sectors, namely 
those related with health and ICT and figure 3.3 shows the 
evolution of R&D investment for these sectors over the 
period 2006-2014.
The salient points from table 3.5 and figure 3.3 are the 
following:
• Overall, the US has 3 times more companies and 3 times 
more R&D investment than the EU in these industries 
whereas the US has only 36% more total R&D than the EU 
in the Scoreboard.
• The Pharmaceuticals sub-sector is the only one where the 
EU and the US have similar numbers of companies, R&D 
investment and R&D intensity. 
• In the Biotechnology sub-sector, the US dominates the 
EU in number of companies (6 times more numerous), 
R&D investment (11 times larger) and larger average 
R&D intensity per company. A particular strength of the 
US lies in its large biotech companies such as Amgen, 
Gilead Sciences, Biogen, Celgene and Regeneron. These 
companies have grown fast through the early adoption 
of biotech and development of successful biotech drugs 
(they all have blockbuster drugs on the market). Most of 
them are now sufficiently large that they are unlikely to be 
acquired by pharmaceutical companies.
• In the ICT industries a large gap in number of companies 
and level of R&D investment is observed across all sectors, 
especially in Semiconductors and Computer Hardware but 
also in Software and Internet. The US has led the way in 
the development of software/internet companies such as 
Google, Facebook, Twitter, Linkedin, eBay and Amazon.
• In the period 2006-2014 the EU/US gap, measured as 
the R&D ratio between the US and the EU companies, 
significantly increased from 2.8 to 3.9 for the IT hardware 
sector.  For Software & Services it changed from 8.6 to 9.5 
and only from 1.4 to 1.5 for health related sectors.
Apart from the above mentioned figures, it is worth 
emphasising the significant number of successful EU 
companies in these sectors that have established market-
leading positions in their sub-sectors (see chapter 4). In fact, 
the Scoreboard contains world-leading EU companies of 
substantial size in these industries. The following examples 
illustrate this point:
• Novo Nordisk from Denmark (and Novozymes which 
was demerged from Novo Nordisk in 2000). The reason 
is that Novo Nordisk is the world leader in treatments for 
diabetes, the world’s fastest growing major disease, with 
around a 50% global market share. Novozymes is the 
world leader in industrial enzymes for household products, 
biofuels and bioenergy.
• ASML from the Netherlands is the world leader in precision 
lithography, the key step in making all semiconductor chips. 
It has around an 80% global market share and is the only 
company with next generation EUV (extreme ultraviolet) 
systems with customers. It has strong links with key firms 
such as Intel, Samsung and TSMC.
• ARM from the UK is the world leader in low power 
consumption semiconductor chip designs for mobile 
devices. ARM chips are in 95% of the world’s smartphones 
and 80% of all digital cameras. Over 60 billion ARM chips 
have been shipped to date and ARM is a leader in the 
global technology hardware sector.
• Dassault Systèmes from France is a world leader in 3D 
CAD design software and product lifecycle management. 
3D design is essential for additive manufacturing (3D 
printing).
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Table 3.5 - Sample of EU and US companies in health and ICT related sectors.
Industry
# companies R&D in 2013 (€m) R&D intensity (%)
EU US EU US EU US
Health  
Pharmaceuticals 50 45 29.8 32.8 13.1 15.2
Biotechnology 19 116 1.5 16.4 18.0 23.1
Health Care Equip. & 
Services
20 60 3.8 7.8 5.0 3.1
IT hardware
Semiconductors 16 72 4.1 27.2 16.5 17.7
Computer Hardware 5 25 1.2 14.6 8.9 4.9
Telecommunications 
Equipment
13 31 9.6 15.0 16.1 13.8
Electronic Office 
Equipment
1 2 0.1 0.5 5.7 2.7
Software & services
Software 30 101 4.9 28.3 15.0 15.4
Computer Services 14 33 1.4 7.0 5.4 6.9
Internet 2 22 0.2 13.2 8.6 16.3
Total 170 507 56.7 162.8
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
Figure 3.3 - R&D investment 2006-2014 for the EU and US companies in health and ICT sectors (€bn).
0	   10	   20	   30	   40	   50	   60	  
R&D-­‐2014	  
R&D-­‐2006	  
R&D-­‐2014	  
R&D-­‐2006	  
U
S	  
EU
	  
Health	  	  	  
IT	  hardware	  
So<ware	  &	  
services	  
Note: Figures refer to 132 EU companies and 371 US companies that reported R&D over the whole 2006-2014 period.
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD. 
4 .  H i g h - p e r f o r m i n g  R & D - d r i v e n  i n n o v a t o r s  i n  t h e  E U
53
The objective of this chapter is to identify EU Scoreboard 
companies, which show high performance over time, and 
to look at their main characteristics in terms of sector of 
activity, location, size and age. The identification of high-
performing firms and the possible determinants of their 
growth trajectories is an important economic and policy 
issue. These firms, leading the introduction of innovations 
and the development of new products and processes, play 
major role for jobs creation and economic growth. 
The conditions that favour firms’ growth are multiple and 
few studies to date have included the economic and growth 
prospects, the influence of the institutional, regulatory 
and business environment (e.g. administrative burden for 
business creation), availability of early-stage finance, the 
market potential or income growth, the stage of economic 
development, the education level and the quality of human 
resources, and also the industry-, firm- and leader-specific 
features as well as the wider stakeholder expectations on 
future growth. 
The analysis presented in this chapter is based on the 
enlarged sample of the top 1000 EU R&D companies (2014 
Scoreboard edition11). The identification of “high-performing” 
companies within this sample of EU R&D driven innovators 
proceeds in two steps. The first step identifies firms with 
positive R&D investment performances on the short and 
longer term, applying for this purpose a set of sound growth 
rates calculations over the 2000-2013 period. The resulting 
sample (459 companies) is then characterized according 
to specific corporate attributes including the geographical 
origin, the technological intensity, the age and the growth 
of labour productivity, net sales and employment. In a 
second step, the selected companies are further screened 
both in relation to their sector’s benchmark and in absolute 
terms. Multiple performance criteria are applied in order to 
identify “high-performing” companies (e.g. “high-growth” 
of R&D and sales indicators, “high R&D intensity” criteria, 
11 This sample includes 633 EU companies ranking in the world top 
2500 and the 367 next largest companies ranked by level of R&D 
investment in 2013. These companies all had R&D investments 
exceeding €5.0 million in 2013.
high labour productivity and positive profits). The set of 
selection criteria is not based on any pre-defined conception 
of “high-performance” and rather considers a wide typology 
of good performing R&D-driven innovators showing further 
grow potential. Hence, the resulting list does not pretend 
to be exhaustive. The last section gives an overview of 
the corporate characteristics of the resulting list of “high-
performing” companies.  
Key findings
The findings of this chapter confirm that Europe can rely 
on a relevant in-house potential to increase the relative 
importance of its high R&D intensive sectors as well as to 
speed up the upgrading of its more traditional and less R&D 
intensive industries. Both aspects are important to build up 
a globally stronger and technologically more competitive 
industry. Salient points for the chapter are:     
• EU Scoreboard companies showing positive growth of 
R&D are concentrated in few countries including the UK, 
Germany, France and Sweden, respectively. The majority 
of these R&D investors operate in high and medium-high 
technology sectors. Among these, high-tech firms are, on 
average, younger than those in other sector groups and 
are also relatively more numerous.
• High-performing EU R&D-driven innovators show very 
heterogeneous corporate trajectories. They include 
dynamic firms, mainly from the ICT-related sectors and 
few older companies from the medium-high and or low 
technology sectors.
• Eight of these high-performing firms show particularly 
strong R&D intensity (above 10%) coupled with strong 
net sales growth (above 10% in the period 2005-2013), 
positive profits and well above sectoral labour productivity 
average: Dialog Semiconductor, Gameloft, Bavarian Nordic, 
Wirecard, Parrot, Playtech, HMS Networks and Generix.
4. High-performing R&D-driven 
innovators in the EU
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4.1 Overview
The Figure 4.1 shows the geographical distribution of the EU 
companies located in the top six EU countries and operating 
in the top six sectors (in both cases in terms of overall number 
of companies). These sectors include: Industrial Engineering, 
Software & Computer Services, Pharmaceuticals & 
Biotechnology, Electronic & Electrical Equipment, Technology 
Hardware & Equipment and Automobiles & Parts industries. 
These 400 companies in the top countries and sectors (40% 
of the EU top 1000 sample) spend more than 100 billion of 
euros (about 60% of the total R&D investment made by the 
EU top 1000 companies in 2014).
Figure 4.1 - Sectoral distribution of top EU countries in selected sectors (by number of companies)
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Note: the overall number of companies represented in Figure 4.1 is 400. 
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
4 .  H i g h - p e r f o r m i n g  R & D - d r i v e n  i n n o v a t o r s  i n  t h e  E U
55
The distribution shows a high concentration among the top 
five countries, which have companies active in all six top 
sectors, with Italy active in only four (not represented in 
Software & Computer Services and Technology Hardware & 
Equipment). 
Different patterns can be observed in terms of country-sector 
representation. The UK is by far the largest contributor to 
the Software, Hardware and Biopharma sectors, Germany to 
Industrial Engineering and Automobiles and Parts, with both 
countries driving the Electronic & Electrical sector. Among 
the other countries, Sweden and France show a diversified 
activity in terms of number of companies across all six 
sectors. Sweden has a higher representation in Industrial 
Engineering and Biopharmaceuticals while France is in 
second position in Software and holds second position with 
the Netherlands in Technology Hardware. With less than 30 
companies in each case, Italy concentrates one third of their 
companies in Industrial Engineering and the Netherlands, 
one fourth in Technology Hardware & Equipment. 
 
4.2  R&D growing companies in 
the top EU-1000 ranking
This section introduces a first distinction of companies based 
on their R&D performances. An initial filter distinguishes 
companies according to the corporate resources committed 
in R&D investments. A second set of criteria enables further 
selection of companies on the basis of their R&D growth 
performances in the long and short term. Box 4.1 describes 
the R&D indicators and growth criteria considered.  
Considering the trade-off existing between observing firms 
for a longer time period and having a relatively large number 
of observations, the selection has been made on the period 
2005-2013. There is, of course, an element of arbitrariness 
in such a decision, but we note that our period of analysis 
covers a relatively long time period (spanning from the years 
before the financial crisis until the most recent available year), 
and also that the number of observations falls relatively 
sharply if a longer time period is taken. Accordingly, the 
selection leads to a sub-sample of 459 firms with positive 
R&D growth rates. 
Within the resulting first sample of 459 companies with 
positive R&D growth rates, four countries account for more 
than two thirds of the companies: UK and Germany (one 
quarter each), France and Sweden. In terms of sectors 
covered, firms are concentrated in high and medium-high 
technology sectors (respectively 191 and 206 firms). Some 
companies from the medium-low and low technology 
sectors are also found (29 and 33 respectively). A closer look 
at the individual sectors shows that together the sectors 
of Industrial Engineering (14%), Software & Computer 
Services (13%), Pharmaceuticals & Biotechnology (12%) and 
Electronic & Electrical Equipment (10%), represent half of 
the companies identified on the initial R&D growth criteria.
More information on how these companies are split between 
sector classes can be found in Figure 4.2. More than half of 
companies from Germany are in high-tech or medium-high 
tech sectors, with a slightly smaller share of the companies 
in high-tech sectors for France and Sweden, respectively. 
UK shows quite similar shares for each sector group with 
a relatively smaller percentage in the medium-high tech 
sectors. Sweden and Denmark and, to the greatest extent 
Belgium, show a relatively large share of companies in 
low-tech sectors. Some countries with only one company 
obviously have this company in only one category: either 
high-tech (Greece, Hungary, and Slovenia), medium-high 
(Malta) or medium-low (Poland, Portugal). 
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Box 4.1 - Selection criteria for R&D performance  
The following criteria are considered :
(1) The R&D intensity: an initial distinction is made at a 1% threshold of corporate R&D intensity in 2013. Among the 
EU 1000 companies, 803 companies have a value of R&D intensity superior to 1%. 
(2) The growth patterns of R&D investment: companies are further investigated on the basis of their pattern of R&D 
growth over and across years. Following on from the focus of firms with R&D intensity above 1% (from (1)), the 
average of the annual growth rates (AAGr) and the compound annual growth rate (CAGr) of R&D investments are 
computed for different sub-sets of the period 2000-2013. A broader understanding of the growth performance of 
R&D expenditures of these firms is provided by the computations of log changes (i.e. log-difference growth rates) and 
compound log annual change*. 
The following table presents the distribution of negative and positive corporate growth rates according to the indicators 
considered.
Growth rate indicators Number of positive corporate rates†
Number of negative 
corporate rates†
Average Annual Growth 
rates
Average Annual Growth 
rate  (AAGr) 
744 56
Average Annual Log 
Growth rate  (AAlogGr)
697 103
Compound Annual  Growth 
rates Growth rates (annual 
change or log annual 
change)
CAGr13 (2013 vs 2000) 171 34
CAGr12 (2013 vs 2001) 229 42
CAGr11 (2013 vs 2002) 262 49
CAGr10 (2013 vs 2003) 278 56
CAGr9 (2013 vs 2004) 416 68
CAGr8 (2013 vs 2005) 480 77
CAGr7 (2013 vs 2006) 514 89
CAGr6 (2013 vs 2007) 551 117
CAGr5 (2013 vs 2008) 565 143
CAGr4 (2013 vs 2009) 585 150
CAGr3 (2013 vs 2010) 596 165
† positive or negative and non-missing.
In order to consider the performances of companies on the short and longer term, only companies with positive growth 
rates of R&D expenditures with respect to the four indicators are maintained in the sample. This procedure allows also 
smoothing the potential high annual fluctuations observed at the company level.
*Note: the calculation of growth rates is not a trivial matter. For example, if a firm grows from x=100 (at time t=1) to x=200 (t=2) and then reverts 
back to x=100 (t=3), the common method for calculating growth rates would consider this to be a 100% increase followed by a 50% decline, 
suggesting perhaps a positive average growth rate of around +25% - even if it did not change size over the period. Instead, the best way of 
calculating growth rates is to take log-differences or ‘log changes’- see the discussion in Tornqvist, L., P. Vartia and Y.O. Vartia (1985). How should 
relative changes be measured?, American Statistician, 39(1), pp. 43–6.
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Table 4.1 presents further information on the characteristics 
of firms in different sector groups (high-tech, medium-high, 
medium-low and low-tech). High-tech firms are, on average, 
younger and smaller than those in other sector groups. 
Together with the medium-high tech group, they constitute 
the largest group in numbers. Firms operating in medium-
tech sectors are on average four times bigger than those 
in high-tech and substantially older. Medium-low and low-
tech firms, in contrast, are quite rare in this sample; they are 
also older than the high-tech ones and have an average size 
ranging between the size of high and medium-tech firms.
 
 
Table 4.2 presents further information on the companies 
according to their age12. The cut-off points for the four age 
classes (<20, 20-49, 50-99, and > or = 100 years) are 
chosen to keep the four groups roughly equi-populated. 
Labour productivity, in turn, is defined as the total sales 
divided by the total number of employees (also known as 
“labour revenue productivity”). Firms in the youngest age 
group (of less than twenty years) exhibited the fastest 
labour productivity growth over the period (about 30.3%). 
The rapid productivity growth of this group of young firms 
can be attributed to their particularly rapid growth of sales 
– the youngest age group also had the highest sales growth 
(group average of 93.6%) in addition to having the highest 
employment growth rate (average of 65%). 
12 The age of the companies is calculated as the number of years from the foundation 
date. The foundation date of a company may refer to the historical foundation date of 
the business, or to the creation of a new business via mergers and acquisitions, or spin-
offs (i.e. the divisions of companies become independent businesses). Hence, a firm’s 
age ‘clock’ can be reset to zero if it changes its incorporation status or is acquired.
Figure 4.2 - Country distribution of companies across sector classes.
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Note: in brackets the number of companies for each country
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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The second age group consists in firms from the category 
20-49 years. As for the first class, this group also shows very 
high sales growth. However they recorded the lowest rate of 
labour productivity growth out of all of the age classes (only 
8%), as employment has increased in similar proportions. 
For the two remaining age classes, the growth of net sales 
and labour productivity is roughly comparable across age 
ranges. Older firms exhibit somewhat higher values for 
both sales growth (45.1% and 49.9% respectively) and 
employment growth (24.3% and 31.3% respectively).
Table 4.1 - Average ages and numbers of firms by R&D intensity group.
Sector Average age (years) Number of firms Average size (thousand employees)
high 46 188 10
medium-high 82 204 42
medium-low 71 29 21
low 110 32 29
Note: Sector groups as defined in Box 1.1
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
Table 4.2- Average labour productivity growth by age class.
Age class Net Sales growth (%) Employment growth (%) Labour productivity growth (%)
<20 yrs 93.6 65 30.3
20-49 yrs 70.8 62.7 8.0
50-99 yrs 45.1 24.3 23.7
> or = 100 yrs 49.9 31.3 19.5
Average 63.0 45.7 18.3
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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Figure 4.3 expands on our analysis of the ages of 
our companies. The youngest firm is found in mobile 
telecommunications, which is not surprising, perhaps, 
considering the recent emergence of new niches and 
subsectors in this industry. Amongst the largest sectors, the 
Software and Hardware sectors are dominated by firms in 
the two younger categories. Some other new industries such 
as Alternative Energy and Biotechnology also appear to be 
composed of relatively young firms. In contrast, sectors such 
as Financial Services, Life Insurance and Banks are composed 
of old firms, as well as some mature technology sectors 
such as Industrial Metals, Mining, Automobiles, Tobacco and 
Chemicals.
4.3  High-performing R&D-
driven innovators 
Starting from the sample of 459 firms previously identified, 
an identification of high-performing firms has been carried-
out on the basis of multiple performance criteria. The final 
set of companies presented in table 4.3 are the result of 
applying two scenarios of performance indicators’ value.
Scenario 1 – Sector based indicators
This first scenario combines additional R&D growth criteria 
with a set of economic performance indicators including 
labour productivity, net sales and operating profits. In order 
to account for the industry differences, alternative industry-
specific thresholds for the indicators values are considered. 
Figure 4.3 - Sectoral distribution of age classes. 
0%	   20%	   40%	   60%	   80%	   100%	  
Industrial	  Engineering	  (65)	  
So;ware	  &	  Computer	  Services	  (59)	  
PharmaceuFcals	  &	  Biotechnology	  (57)	  
Electronic	  &	  Electrical	  Equipment	  (47)	  
Technology	  Hardware	  &	  Equipment	  (30)	  
Health	  Care	  Equipment	  &	  Services	  (25)	  
Automobiles	  &	  Parts	  (22)	  
Chemicals	  (20)	  
Aerospace	  &	  Defence	  (17)	  
Support	  Services	  (14)	  
Other	  (14)	  
Household	  Goods	  &	  Home	  ConstrucFon	  (14)	  
General	  Industrials	  (13)	  
ConstrucFon	  &	  Materials	  (9)	  
Food	  Producers	  (8)	  
Banks	  (7)	  
Fixed	  Line	  TelecommunicaFons	  (6)	  
Industrial	  Metals	  &	  Mining	  (6)	  
Personal	  Goods	  (5)	  
Travel	  &	  Leisure	  (4)	  
General	  Retailers	  (4)	  
Media	  (4)	  
AlternaFve	  Energy	  (3)	  
Leisure	  Goods	  (3)	  
Mining	  (3)	  
<20	  yrs	   20-­‐49	  yrs	   50-­‐99	  yrs	   >=100	  yrs	  
Note:  in brackets the number of companies for each country. Only industries with more than 3 companies are shown. Other include Financial Services 
(2 companies), Oil Equipment, Services & Distribution (2), Industrial Transportation (2), Electricity (2), Life Insurance (1), Tobacco (1), Forestry & 
Paper (1), Beverages (1), Real Estate Investment & Services (1) and Mobile Telecommunications (1).
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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The initial selection of firms is made according to the 
following criteria:
• A compound annual growth rate of R&D above 15% on the 
period 2005-2013;
• An average labour productivity growth above the median 
of the industry on the period 2005-2013;
• An average net sales growth above the median of the 
industry on the period 2005-2013 and;
• Positive operating profits in 2013. 
The application of these criteria selects 43 firms which are 
to be found in all technological sector-groups, although 
more frequently in high-tech or medium-high tech sectors. 
Firms that are selected under this scenario have a high 
growth of R&D, as well as showing high growth of labour 
productivity, growth of sales and positive operating profits in 
the last year of available data (2013). They are taken from a 
variety of different sectors, although those that feature the 
most prominently include Pharmaceuticals & Biotechnology, 
Software & Computer services, and Technology Hardware 
& Equipment. In keeping with our previous results, this 
scenario draws on a large number of countries, although 
the ‘usual suspects’ stand out in particular, the UK, Germany, 
France, and Sweden are quite visible. They also display 
heterogeneity in their other dimensions, with perhaps the 
most striking heterogeneity being in terms of their size (in 
terms of employees) – the firms range in size from 146 
employees to 97,869 employees, such that one firm may 
be hundreds of times larger than another firm in the same 
scenario grouping. 
Within this first selection, a sub-group of 18 companies 
(marked by a star in Table 4.3) are distinguished on the basis 
of stricter criteria as follows:
• A compound annual growth rate of R&D above the 75th 
percentile of the industry on the period 2005-2013;
• An average labour productivity growth above the 75th 
percentile of the industry on the period 2005-2013;
• An average net sales growth above the 75th percentile of 
the industry on the period 2005-2013 and ;
• Positive operating profits in the last year.
The application of these criteria leads to a very small set of 
companies all active in high (10 firms) or medium-high (7) 
technology sectors, but a company from the Netherlands. 
These top R&D investors have a relative outstanding 
performance in relation to their sector peers and for the 
performance indicators used. These firms all hail from high- 
(with Technology Hardware & Equipment and Software & 
Computer Services in particular, being well represented) 
and medium-high-technology sectors including companies 
from the Industrial Engineering and Electronic & Electrical 
Equipment sectors. These firms come from a range of 
European countries with a prominent representation of the 
UK, France and Germany. Again, we can see a remarkable 
heterogeneity across firms in all dimensions, and particularly 
in terms of the dispersion of R&D intensity (ranging from 1% 
in several cases to 40% and even 45%), operating profits, 
and also number of employees.
Scenario 2 – Absolute R&D intensity and R&D and net sales 
growth indicators
The 43 high-performing companies identified using the 
indicators of scenario 1 described above constitute only one 
of the multiple possible selections. In order to identify other 
possible high-performing R&D driven innovators, alternative 
criteria has been applied to the initial sample of 459 firms 
with positive R&D growth in the period 2005-2013: 
• An R&D intensity superior to 10%
• A compound annual growth rate of R&D above 10% on the 
period 2005-2013;
• An average net sales growth above 10% on the period 
2005-2013 and;
• Positive operating profits in 2013. 
The application of these criteria led to a sample of 41 firms, 
including 18 companies already identified in scenario 1 
(underlined in light blue) and 23 new companies.  
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4.4  Overview of the corporate 
characteristics of the high-
performing R&D-driven 
innovators.
This section outlines the characteristics of the 66 companies 
identified in the previous section as the high-performing 
R&D-driven innovators. These companies all have an R&D 
intensity above 1%, a compound annual R&D growth above 
10% on the period 2005-2013, positive net sales growth 
and operating profits in 2013.
A first observation is that the country and sector distributions 
are quite similar to those of the 459 firms listed from the 
first step (i.e. R&D intensity above 1% and positive R&D 
growth). Indeed both in terms of countries and sectors, our 
‘usual suspects’ are well featured in this restricted sample, 
although some noticeable variations may be observed. The 
UK with about one third of the 66 companies is still leading 
the group in terms of number of companies, while Germany 
remains second but with a lesser proportion of companies, 
about one fifth of the companies (as compared to about one 
quarter each in the 459 firms sample). Sweden is now more 
represented than France in the high-performing R&D-driven 
innovators group (respectively 12 and 9% of companies). 
In terms of sectoral representativeness, the same 
concentration in high- and medium-high tech firms shows up 
in the 66 firms listed; they represent about 90% of the total 
number of companies. Within the high tech group of firms, 
Biopharma and Software industries feature prominently while 
Electronic & Electrical Equipment and Industrial engineering 
are again dominant in the medium high tech group of firms. 
Although with different rankings, these four industries were 
already prevailing in the first step. 
Within the group of 66 companies some EU R&D driven 
innovators, mostly from the biopharma and ICT-related 
industries, comply with both the criteria considered for the 
first step of scenario 1 and those selected for the scenario 2 
(18 underlined in blue in table 4.3). 
Eight outstanding companies that are worth noticing include 
Dialog Semiconductor, Gameloft, Bavarian Nordic, Wirecard, 
Parrot, Playtech, HMS Networks and Generix (marked with 
a star and underlined in blue in the table 4.3). They record 
particularly strong R&D intensity (above 10%), positive 
profits in 2013 and well above sectoral R&D growth, net 
sales growth and labour productivity average. They are in 
general young firms founded or established between the 
end of the eighties and the end of the nineties and mostly, 
but not exclusively, include firms from the high tech sectors 
(ICT-related sectors, in particular, Technology Hardware & 
Equipment and Software and Computer Services). Importantly 
in this group the corporate acquisitions constitute one of 
the key dimensions of the growth strategy. Furthermore the 
maximum values for the R&D growth are observed in this 
group, which also presents the higher growth rate in average. 
Of the 23 new entities identified only on the basis of the 
scenario 2 (where industry-specific values are not considered), 
more than one third of the firms are from the UK, followed 
by Sweden having 3 out of its 4 companies in health-
biopharma industries. The other countries, but Finland with 
two software companies, only have one company represented 
each, including Austria, Belgium, Denmark France, Italy and 
Malta. These 23 new companies contain a number of world 
class EU R&D companies that have global market positions. 
Few of them illustrating the diversity of activities amongst 
successful and innovative EU firms, include:
• Companies operating in ICT-related industries such as ARM 
in low power consumption chip for  smartphones and digital 
cameras;  AVEVA in 3D engineering design software for 
complex structures such as oil & gas rigs, power stations 
and ships; 
• Companies in biopharma industries as for instance 
MorphoSys (therapeutic antibodies), Novo Nordisk 
(treatments for diabetes) and Shire (treatments for rare 
diseases and other specialised conditions) and;
• Companies in medical instruments as Elekta (radiotherapy 
systems), in general industrials as Dyson (bagless vacuum 
cleaner, innovative fans, heaters, hand driers, lighting and 
tools) and more diversified companies such as Renishaw, 
which has products in precision metrology, precision 
healthcare and additive manufacturing (3D printing in 
metals) and serves a wide range of industries from jet 
engine and wind turbine manufacture to dentistry band 
brain surgery.
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5  Location of companies’ economic 
and innovation activities
It is crucial for policy makers to understand better the actual 
geographic distribution of companies’ activities to improve 
the effectiveness of policies aimed to support specific 
industries. Currently, the Scoreboard allocates companies 
to the countries where they have their headquarters (HQ); 
however, companies often operate in several countries and 
may have diverse locations for their decision, production 
and innovation centres. Different location choices -due to 
market strategies, optimisation of costs or fiscal purposes- 
have important policy implications and affect the analysis 
of economic and R&D trends of companies aggregated by 
country and region. 
The objective of this chapter is to improve the characterisation 
of companies regarding the location of their economic and 
innovation activities in order to obtain a first estimate of 
the actual distribution of jobs, value-added and knowledge 
across countries and regions. 
First, an overview of the location of companies’ activities 
is presented, showing the worldwide distribution of 
their subsidiaries. Then a pilot exercise is carried out for 
a representative sample, using information from the 
annual reports and accounts of parent companies and 
their subsidiaries. Finally, the location of the innovation is 
estimated by analysing the patent portfolio of the whole 
Scoreboard sample, focusing on the international location of 
companies’ affiliated inventors.   
Key findings
• A number of companies do not show any activity in their 
headquarter country. These are mainly companies from 
the Cayman Islands and Bermuda (94) that have been 
reassigned to China (80), US (7), Taiwan (5) and Singapore 
(2), where they have their main economic centres. 
• The country distribution of patents filed by a company’s 
subsidiaries offer a good proxy for the location of 
companies’ innovation activity. This analysis shows that 
80% of patents were developed by inventors residing in 
the same world region as the HQ of the parent company 
that owns the rights.  
• Patent analysis for the Pharmaceuticals & Biotechnology 
sector shows the US lead in this sector: 81.2% of patents 
by US companies are nationally developed and it is the 
preferred location to develop international inventions by 
all other world regions (21.6% of patents by EU companies 
and 43.7% by Swiss companies).
• Patent analysis for the Automobiles & Parts sector shows 
that companies based in Japan and the EU hold 77% 
of patent families in the sector. The EU is particularly 
attractive for the development of inventions by the other 
regions (28.1% of patents by US companies) and almost 
85 % of patents by EU companies are domestically 
developed. 
5.1 Introduction  
Preliminary information on the location of companies’ 
activities is provided by examining the geographic 
distribution of the subsidiaries of the Scoreboard companies. 
We retrieved information on the ownership structure for 
2255 companies (out of the 2500 Scoreboard sample), 
accounting for 271533 subsidiaries scattered around the 
world (excluding branches13). 
A total of 215 countries and independent territories host at 
least one subsidiary of a Scoreboard company (figure 5.1). 
13 The very high number of branches in the sample hides an extremely skewed 
distribution across companies, providing unreliable figures on the network size of some 
company. Moreover, there are large country and industry differences in the share of 
branches. For these reasons we decided to drop branches from the analysis.
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We split the group of subsidiaries between international 
(i.e. located in a country different from the HQ) and national 
(i.e.  located in the same country as the HQ). In the sample, 
177443 (64.3%) subsidiaries are international, 94090 are 
national (see Table 5.1). 
The country where the majority of the international 
subsidiaries are located is the US, followed by the UK 
and China. The ratio between international and national 
subsidiaries is higher in countries where less Scoreboard 
company HQs are located.
Figure 5.2 looks at the number of Scoreboard companies 
present in a country, either through their HQ or by means of 
at least one of their subsidiaries, while table 5.2 focuses on 
the top 20 countries by presence of Scoreboard companies 
There are countries where the Scoreboard companies are 
much more present than looking just at the HQ location 
would suggest. Apart from the extreme cases of countries 
hosting only one Scoreboard company HQ, we have countries 
like Spain, Belgium or Italy that experience a very consistent 
presence of Scoreboard companies inside their boarders 
even if the number of HQs located there is relatively low.
Fig 5.1 - Subsidiaries (both national and international) by country of destination.
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Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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Fig 5.2 - Scoreboard companies presence (both through their HQ or at least one subsidiary).
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Table 5.1 - international vs national subsidiaries by country of destination (top 20 countries).
Country
n. of international 
subsidiaries by country of 
destination
n. of national subsidiaries 
in the country
ratio (international over 
national subsidiaries)
US 38578 39538 0.98
UK 15435 7312 2.11
China 10307 6504 1.58
Germany 8688 7294 1.19
Japan 1924 11361 0.17
France 5360 7196 0.74
Netherlands 6390 1147 5.57
Canada 6655 282 23.6
Australia 5049 1340 3.77
Spain 3672 2290 1.6
Italy 3560 1634 2.18
Mexico 3896 38 102.53
Brazil 3364 262 12.84
Russian Federation 2036 1267 1.61
Sweden 2243 1060 2.12
India 2400 401 5.99
Switzerland 2268 530 4.28
Singapore 2760 38 72.63
Ireland 2411 334 7.22
Malaysia 1661 660 2.52
Other countries 
(185)
48786 3602 13.54
Total 177443 94090 1.89
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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This shows the widespread geographic distribution of 
companies’ activities and confirms that allocating the 
whole company activity to the HQ location significantly 
underestimates the effects of cross-border activities. 
However, in a globalised world a successful company needs 
to have a substantial presence in all the main world regions. 
Furthermore, some R&D needs to be located in each region 
to ensure that new products take into account the special 
needs of each region. Therefore, this complexity needs to 
be taken account of when analysing the economic and R&D 
trends of groups of companies aggregated by country and 
world region. For example, a European or Asian biopharma 
company is likely to be less successful if it has no R&D 
located in the US which is the most important drug market in 
the world with the highest concentration of biopharma R&D. 
An important benefit of the country and regional analyses 
presented in the Scoreboard is the way they show how 
particular countries and regions excel in particular sectors. 
5.2 Pilot analysis on a selected 
sample of companies
A pilot exercise was carried out to test the feasibility of 
assessing the worldwide distribution of companies’ activities 
and in particular of identifying and distinguishing the actual 
location of their economic and innovation activities. A 
sample of 100 companies has been selected according to 
their relevance in terms of R&D investment, type of industry 
(key manufacturing sectors) and country of legal head office. 
The latter criterion focussed on countries where the total 
R&D of the Scoreboard companies largely exceeds the 
country’s official business enterprise R&D, thus indicating 
that the R&D is most likely performed in another country 
(see company sample aggregated by country  in Table 5.3).
Table 5.2 -  Number of Scoreboard companies presented via HQ or subsidiaries by country of HQ (top 20 
countries).
Country
n. of SB companies 
with HQ located in the 
country
n. of SB companies 
present in the 
country through their 
subsidiaries
ratio (SB presence 
through subsidiaries 
over SB presence 
through HQ)
UK 124 1567 12.6
China 270 1398 5.2
Germany 126 1301 10.3
US 733 1255 1.7
Canada 24 1130 47.1
Netherlands 38 1126 29.6
Singapore 5 1119 223.8
France 82 1088 13.3
Brazil 9 1033 114.8
India 24 1008 42
Italy 26 984 37.8
Australia 16 967 60.4
Spain 16 932 58.3
Japan 351 919 2.6
Mexico 1 908 908
Switzerland 51 765 15
South Korea 60 755 12.6
Belgium 16 719 44.9
Russian Federation 3 694 231.3
Sweden 41 693 16.9
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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These companies have been examined one by one using 
all available information from public sources for the 
parent company and for their subsidiaries. The data at the 
parent company level comes from the consolidated report 
comprising main economic and financial indicators, the 
international distribution of assets and sales, address of 
trading office, number of patents, etc.  In a second step, the 
analysis included the information on ownership structure of 
the parent companies and available data on their subsidiaries 
such as the number of subsidiaries per country, turnover, 
employees, assets and patents.
Table 5.3 - Sample of companies for testing actual location of activities. 
Country (headquarter)* # companies analysed # companies showing headquarter different from trading address**
The Netherlands 31 6
Cayman Islands 18 18
Bermuda 17 17
Luxembourg 11 4
Ireland 5 3
UK 4 2
Hong Kong 4 1
Singapore 3 0
France 2 0
Germany 2 0
Liechtenstein 1 0
Japan 1 0
Switzerland 1 0
Notes: * Country where the company has its registered office.
               ** Country where the company carries out its business and where the company`s assets are likely to be found.
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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The combination of all available data for these companies 
show interesting insights on the actual location of their 
economic and innovation activities and a great variety of 
cases. The main conclusions on the pilot exercise are as 
follows:
• There are a number of companies that show no economic 
and innovation activity in the country of their registered 
office (headquarters). These are mainly the companies 
based in Cayman Islands and Bermuda. The extension 
of the analysis to the whole sample of Scoreboard 
companies from these countries confirms this finding 
and allows the reassignment of these companies to the 
countries where they have the main economic centre. The 
94 companies from Cayman Islands and Bermuda in this 
year’s Scoreboard have been reassigned to China (80), US 
(7), Taiwan (5) and Singapore (2).
• Some companies that are highly distributed worldwide 
show a weak relationship between their main economic 
and innovation centres and headquarters but there is not 
enough or conclusive information to reassign them to a 
single country.
• There are cases where a company has intentionally moved 
its HQ for tax reasons. Apart from the Cayman Islands and 
Bermuda, this is the case for several US companies which 
have moved their HQs to Ireland. The most recent large 
example is Medtronic, the world’s largest R&D investor 
in the health equipment sector, which has just acquired 
Covidien and the HQ of the combined company is now 
in Ireland although both companies have most of their 
innovation and much of their production activities in the 
US.
• A clear difference between the economic and innovation 
centres is showed by other companies, in particular in 
the manufacturing sector. It appears that innovation 
(measured by patents) is performed in the home country 
or region whereas the production is carried out abroad, 
often in countries where labour costs are lower.
• The results show a general estimate of the location of 
companies’ economic activity in terms of jobs and value-
added, however a precise calculation is not possible due 
to the lack of information. For example the number of 
employees is often missing for the subsidiaries and even for 
the parent company.   Another limitation is the insufficient 
information provided by companies to distinguish the type 
of activity carried out by the subsidiaries, e.g. production, 
distribution, financing, etc.
• The country distribution of patents filed by the subsidiaries 
seems to be a good proxy to estimate the international 
location of companies’ innovation activity. This is shown in 
the next section where the analysis is extrapolated to the 
whole sample of companies in the Scoreboard.
• The results of this exercise suggest that it is possible 
to extend the approach to analyse value-chains, e.g. 
incorporating data from companies in the supply chain.  
5.3 Patent analysis to assess 
companies’ major innovation 
location
This section focuses on the international dimension of 
innovative activities. In particular, information on the location 
of inventors and owners, as reported in patent documents, 
is used as a proxy for the localization of the R&D activities 
of Scoreboard companies.  In particular, patents are defined 
as international when the location of the inventors differs 
from that of the Scoreboard company legally owning the 
intellectual property rights. In the cases of multi-inventors 
from multiple countries, fractional counts of the same patent 
between the different countries are applied.14 Finally, in 
order to control for the multiple filing of the same invention, 
different patent applications have been matched through 
INPADOC families15 to avoid double counting. An extensive 
analysis of the innovation activities of the world’s top 
corporate R&D investors can be found in Dernis et al. (2015). 
The analysis is carried out using the sample of top 2000 
R&D investors worldwide as reported in the 2014 edition 
of the Scoreboard. The patents filed by these companies at 
the European Patent Office (EPO) and the US Patent Office 
(USPTO) over the period 2010-2012 have been retrieved 
from the PATSTAT16 database in the framework of a JRC-
OECD joint project. The matching has been carried out on a 
by-country basis using a series of string matching algorithms 
contained in the Imalinker system (Idener Multi Algorithm 
Linker) developed for the OECD by IDENER, Seville, 2013. 17
The first section presents a general overview of the patenting 
activities of Scoreboard companies and their distribution 
across main world regions (according to the total patents 
filed and the two patent offices considered). The “Automobiles 
and Parts”, “Pharmaceuticals” and “Biotechnology” sectors 
are further studied. For these sectors, the geographical 
distribution of the patenting activities for the top 20 
companies in terms of R&D investment is also presented.  
14 See Dernis et al. (2001) for a more in depth description of the methodology used.  
15 See definition at: http://www.epo.org/searching/essentials/patent-families/inpadoc.
html
16 PATSTAT is the European Patent Office’s Worldwide Patent Statistical Database 
which contains data about 70 million applications of more than 80 countries. See 
more details at http://www.epo.org. 
17 For a description of Imalinker, see http://www.idener.es/?portfolio=imalinker.
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5.3.1 Distribution of patents by world region
The analysis of the 510,250 patent families that were 
filed during the period under study shows that 80% were 
developed by inventors residing in the same world region as 
the company legally owning the rights. The remaining 20% 
were developed by inventors residing in a different region. 
As reported in table 5.4, the recourse to international 
development of inventions varies across regions.
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 Table 5.4 - Mapping the international location of patenting activities.
Inventor location 
EU USA Japan Asian Tigers Switzerland RoW
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EU 
(102,714)
73.9% 18.9% 0.8% 0.8% 1.0% 4.6%
USA 
(171,699)
10.3% 77.9% 1.5% 1.5% 0.7% 8.1%
Japan 
(145,618)
2.5% 5.0% 91.4% 0.3% 0.05% 0.8%
Asian Tigers 
(61,065)
0.7% 3.8% 0.5% 85.0% 0.01% 9.9%
Switzerland 
(10,483)
37.6% 31.5% 1.4% 0.3% 24.9% 4.3%
RoW 
(18,670)
8.9% 21.4% 0.4% 3.3% 0.6% 65.4%
Note: Patent families are fractional counted in case of multiple inventors and/or multiple applicants. RoW does not include the Asian Tigers and Switzer-
land as in other parts of the present report.  
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
Japan based companies are by far the least internationalised, 
with less than 10% of patent families developed outside 
Japan. On the other side of the spectrum, Switzerland based 
companies develop the vast majority (75%) of their patent 
families abroad, and in particular in the EU (37.6%) and in 
the US (31.5%). The development of patent families in the 
US is largely due to the massive R&D facilities Novartis and 
Roche have there (reflected by their patenting activity, see 
table 5.6 ). 
EU and US based companies appear to be more 
internationalized than the sample average with 73.9% 
and 77.9% of their patent families developed within their 
respective region. However, while 18.9% of EU owned patent 
families are developed by inventors residing in the US, EU 
developed patent families represent 10.3% of the total US 
owned ones. It is worth noting, that if the total number of 
patent families is considered, the difference between these 
two ‘flows’ in not very important (19,443 EU -> US; 17,651 
US -> EU).
Overall, the US appears to be the most attractive region of 
the world for the R&D investment of the top R&D investors 
worldwide.
5.3.2 Distribution of patents by economic area:  pharma 
and biotech sector
Firms in the “Pharmaceuticals and Biotechnology” sector 
have filed 20,352 patent families over the period under 
study. The ratio of patent families with inventors residing in 
the same world region with the applicant is 65%: lower than 
the average of the total sample (80%). Thus, R&D activities 
of firms in this sector look more internationalised than the 
activities of firms in other sectors. Some Japanese biopharma 
companies do take the alternative route of licensing/jointly 
developing with US companies.
In Table 5.5 the distribution of patent families across 
different world regions based on “applicant ” and ”inventor” 
information retrieved from filings by firms in the “Pharma & 
Biotech” sector is presented.
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Figure 5.5 shows that the higher internationalisation 
of the “Pharma & Biotech” sector is due to Japan and 
Switzerland based companies. In particular, Switzerland 
based companies, which hold an important share of patent 
families in this sector (14%), have a rather low proportion 
of nationally developed inventions (less than 1 in 5). The 
share of US based inventors in patent families owned by 
Switzerland based companies is particularly high (almost 44 
%) followed by EU with 31%. 
US and EU based companies hold 75% of patent families in 
the sector. In both cases the share of patent families with 
inventors and applicants residing in the same world region 
are similar to the overall figures. In the case of US based 
companies the proportion of patent families that have been 
nationally developed is slightly higher than the average 
(81.2%). 
In the “Pharma & Biotech” sector US appear particularly 
attractive. Indeed US is the preferred location to develop 
international inventions by all other world regions (followed 
by the EU). This is due to the importance of “Pharma & 
Biotech” companies having US R&D sites in the world’s 
largest drugs market by value. Roche’s ownership of 
Genentech (a very innovative US biotech company) is just 
one example. The US has four advantages as a location – it 
accounts for roughly half the world’s drug market by value, 
almost all the major “Pharma & Biotech” companies have 
R&D based there, it is home to a large number of small and 
mid-sized biotech companies (often attractive acquisition 
targets) and has the availability of a large number of highly 
skilled people.
In tables 5.6 and 5.7 the three most important countries, in 
terms of residence of inventors, for the Top 20 R&D investors 
in the “Pharma & Biotech” sector are shown. In both tables 
companies are ranked according to their R&D investments. 
The distribution of inventors for companies in the 
Pharmaceutical sector is more similar to the overall picture 
than those operating in the Biotechnology one. A high 
proportion of US based inventors is the common pattern 
shown by companies operating in the two sub-sectors. 
In particular, patent families filed by Pharmaceuticals 
companies based in Switzerland and UK are mostly 
developed by US based inventors.
Table 5.5 - Mapping the international location of patenting activities (Pharmaceuticals & Biotech).
Inventor location 
EU USA Japan RoW Switzerland
Co
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EU 
(6,635)
72.2% 21.6% 1.3% 3.9% 1.0%
USA 
(8,619)
10.3% 81.2% 1.7% 5.0% 1.8%
Japan 
(1,342)
5.8% 18.5% 67.8% 7.7% 0.21%
RoW 
(860)
18.1% 30.5% 0.1% 50.3% 1.12%
Switzerland 
(2,897)
31.0% 43.7% 2.6% 3.8% 18.8%
Note: Patent families are fractional counted in case of multiple inventors and/or multiple applicants. RoW does not include Switzerland as in other parts 
of the present report. 
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
T h e  2 0 1 5  E U  I n d u s t r i a l  R & D  I n v e s t m e n t  S c o r e b o a r d
76
Table 5.6 - First three countries of inventor location for the Top 20 Pharmaceuticals companies.
	  
Company	  (n.	  of	  patent) Country R&D	  (2012) Country % Country % Country %
ROCHE	  (1667) CH 7008 US 39.5 DE 27.0 CH 19.6
NOVARTIS	  (1165.75) CH 6923 US 51.8 CH 13.5 DE 13.3
MERCK	  US	  (739) US 5996 US 74.7 NL 8.1 CA 2.9
JOHNSON	  &	  JOHNSON	  (2046) US 5809 US 71.5 CH 5.9 IL 4.7
PFIZER	  (386) US 5740 US 84.2 GB 8.5 DE 1.2
SANOFI-­‐AVENTIS	  (1171.583) FR 4909 DE 31.0 FR 25.0 GB 22.9
GLAXOSMITHKLINE	  (431) GB 4229 US 42.1 GB 31.4 BE 11.8
ELI	  LILLY	  (134.6667) US 4000 US 85.1 ES 5.1 GB 2.5
ASTRAZENECA	  (346) GB 3375 US 45.8 GB 27.3 SE 17.2
ABBOTT	  LABORATORIES	  (1271.5) US 3276 US 84.6 DE 4.5 NL 2.3
BAYER	  (1684.833) DE 3182 DE 64.7 US 19.7 FR 4.9
BRISTOL-­‐MYERS	  SQUIBB	  (311) US 2851 US 94.6 CA 2.0 IN 1.6
TAKEDA	  PHARMACEUTICAL	  (305.5) JP 2840 JP 46.7 US 36.4 DE 8.0
BOEHRINGER	  INGELHEIM	  (497.5) DE 2795 DE 60.3 US 20.7 AT 5.7
OTSUKA	  (45.5) JP 1685 JP 64.8 CN 17.6 DE 8.8
DAIICHI	  SANKYO	  (214) JP 1603 JP 50.2 IN 37.9 US 10.5
ASTELLAS	  PHARMA	  (130.8333) JP 1593 JP 61.0 US 29.6 GB 3.8
MERCK	  DE	  (709.8333) DE 1511 DE 54.8 US 15.8 GB 8.1
NOVO	  NORDISK	  (188) DK 1397 DK 86.5 SE 5.5 US 2.6
EISAI	  (108.5) JP 1054 JP 52.2 US 41.6 GB 4.9
First	  Inventor	  country	  
(2010-­‐2012)
Second	  Inventor	  country	  
(2010-­‐2012)
Third	  Inventor	  country	  
(2010-­‐2012)
Notes:  To facilitate comparisons between companies the length of bars is calculated column wise. 
Patent families are fractional counted in case of multiple inventors and/or multiple applicants.
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
Table 5.7 - First three countries of inventor location for the Top 20 Biotechnology companies.
	  
Company	  (n.	  of	  patent) Country R&D	  (2012) Country % Country % Country %
AMGEN	  (237) US 2562 US 92.1 CA 2.2 DE 1.7
GILEAD	  SCIENCES	  (150.25) US 1334 US 90.9 CA 4.3 BE 0.7
CELGENE	  (140) US 1206 US 92.4 GB 1.3 CN 1.1
BIOGEN	  IDEC	  (86.5) US 1012 US 91.5 GB 3.1 CH 2.9
VERTEX	  PHARMACEUTICALS	  (241.8333) US 572 US 66.1 GB 24.1 CA 6.0
CSL	  (34) AU 280 AU 35.3 DE 23.5 US 19.1
LIFE	  TECHNOLOGIES	  (456.8333) US 259 US 88.6 DE 2.3 IE 1.6
BIOMARIN	  PHARMACEUTICAL	  (29) US 229 US 85.6 CN 8.0 HK 4.6
BIOMERIEUX	  (122) FR 219 FR 68.9 US 18.3 GB 3.7
NOVOZYMES	  (381.5) DK 194 DK 47.2 US 31.6 CN 6.4
ILLUMINA	  (88.5) US 175 US 83.1 IS 6.8 GB 6.2
ALEXION	  PHARMACEUTICALS	  (23) US 163 US 80.4 CA 10.9 GB 3.3
UNITED	  THERAPEUTICS	  (20) US 131 US 77.5 GB 17.5 DE 5.0
SEATTLE	  GENETICS	  (29) US 129 US 80.2 DE 9.5 GB 8.6
NEKTAR	  THERAPEUTICS	  (61) US 118 US 86.1 GB 8.2 CN 4.9
ALKERMES	  (16.5) IE 101 US 97.0 IT 3.0
REGENERON	  PHARMACEUTICALS	  (58.5) US 100 US 95.3 AU 2.6 CH 1.7
EXELIXIS	  (47.5) US 98 US 90.7 GB 4.2 CN 1.1
CUBIST	  PHARMACEUTICALS	  (27) US 96 US 93.8 CH 3.1 IT 1.9
QIAGEN	  (99) NL 93 DE 75.8 US 8.6 AU 7.1
First	  Inventor	  country	  
(2010-­‐2012)
Second	  Inventor	  country	  
(2010-­‐2012)
Third	  Inventor	  country	  
(2010-­‐2012)
Notes:  To facilitate comparisons between companies the length of bars is calculated column wise. 
Patent families are fractional counted in case of multiple inventors and/or multiple applicants. Companies’ names are as reported in 2013 (Bio-
gen has recently dropped Idec from its name).           
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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Biotechnology companies, mainly locate in the US with 80% 
of the companies in table 5.7 having their first inventor in 
the US and the four largest having over 90% of inventors 
based in the US. And most of the others have very significant 
R&D in the US. The US appears to be particularly attractive, 
not only for the development of Biotechnology innovations, 
but also for the location of companies in this sector. This is 
partly because of the large size of the US drug market, the 
many biotech start-ups there (where availability of finance 
and ease of company formation act as attraction factors) 
and the ready availability of skills.
5.3.3 Distribution of patents by economic area: automo-
bile & parts sector
Firms in the “Automobiles & Parts” sector have filed 41,927 
patent families between 2010 and 2012. The proportion of 
patent families with inventors residing in the same world 
region with the applicant is about 84%, somewhat higher 
than the average. 
In Table 5.8 the distribution of patent families across 
different world regions based on “applicant ” and ”inventor” 
information retrieved from filings by firms in the “Automobile 
& Parts” sector is presented.
Table 5.8 - Mapping the international location of patenting activities (Automobiles and Parts).
Inventor location 
EU USA Japan Asian Tigers RoW
Co
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EU  
(14,609)
84.9% 10.6% 1.2% 0.9% 2.4%
USA 
(7,172)
28.1% 65.8% 0.8% 0.4% 4.8%
Japan 
(17,508)
1.6% 7.8% 89.9% 0.0% 0.58%
Asian Tigers 
(2,520)
0.2% 0.8% 0.4% 97.0% 1.54%
RoW 
(118)
71.4% 5.3%   23.3%
Note: Patent families are fractional counted in case of multiple inventors and/or multiple applicants. RoW does not include the Asian Tigers and Swit-
zerland as in other parts of the present report. 
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
T h e  2 0 1 5  E U  I n d u s t r i a l  R & D  I n v e s t m e n t  S c o r e b o a r d
78
The behaviour of Japanese and US based companies is 
the opposite of what is observed in the Pharmaceutical & 
Biotech sector. On the one hand, the innovation activities of 
Japanese companies operating in the Automobile and Parts 
sector appear to be rather highly concentrated in Japan. 
On the other hand, US companies present a high degree 
of internationalization with almost 30% of patent families 
developed by EU based inventors. Japan and EU based 
companies hold 77% of patent families in the sector. But 
while for Japanese companies the share of patent families 
with national inventors is similar to the overall figure, in the 
case of EU based companies a higher than the average share 
of inventors residing in the EU is observed (almost 85%).
In table 5.9 the three most important countries, in terms 
of residence of inventors, for the Top 20 R&D investors in 
the Automobile and Parts sector are shown, companies are 
ranked according to their R&D investments. 
Most of the top R&D investors operating in the Automobile 
and Parts sector tend to develop their technologies “in-
house”. Indeed, in most cases the headquarter is also the 
place where the majority of technologies are developed. 
Exceptions are represented by Fiat (due to the acquisition of 
Chrysler), Tata Motors (due to the acquisition of Jaguar/Land 
Rover) and Delphi (which started off as the parts arm of GM). 
 
Table 5.9 - First three countries of inventor location for the Top 20 Automobile & Parts companies.
	  
Company	  (n.	  of	  patent) Country R&D	  (2012) Country % Country % Country %
VOLKSWAGEN	  (1731) DE 9515 DE 74.3 SE 17.0 CZ 2.7
TOYOTA	  MOTOR	  (4063) JP 7071 JP 87.1 US 11.4 CA 0.7
DAIMLER	  (358) DE 5639 DE 89.2 US 6.2 CA 3.0
GENERAL	  MOTORS	  (4546) US 5584 US 76.5 DE 14.5 IT 2.1
ROBERT	  BOSCH	  (4883) DE 4924 DE 73.4 US 10.7 FR 2.2
HONDA	  MOTOR	  (3034) JP 4906 JP 81.8 US 15.7 DE 1.6
FORD	  MOTOR	  (144) US 4169 US 66.9 DE 14.2 CA 7.6
NISSAN	  MOTOR	  (876) JP 4115 JP 92.6 GB 4.4 ES 1.0
BMW	  (516) DE 3952 DE 93.7 AT 3.2 US 1.7
FIAT	  (445) IT 3295 US 39.5 IT 34.0 DE 22.0
DENSO	  (2673) JP 2938 JP 95.6 US 3.5 IT 0.4
PEUGEOT	  (PSA)	  (843) FR 2481 FR 82.2 DE 8.5 US 7.3
RENAULT	  (350) FR 1889 FR 98.5 ES 0.9 CH 0.1
CONTINENTAL	  (1078) DE 1827 DE 61.9 US 18.0 IT 6.9
TATA	  MOTORS	  (80) IN 1496 GB 86.3 IN 6.3 US 5.9
AISIN	  SEIKI	  (1231) JP 1183 JP 93.9 US 4.9 FR 0.4
SUZUKI	  MOTOR	  (268) JP 1044 JP 99.6 GB 0.4
HYUNDAI	  MOTOR	  (1575) KR 934 KR 98.6 US 0.7 JP 0.4
DELPHI	  (523) GB 910 US 67.0 DE 9.6 FR 9.4
ZF	  (605) DE 848 DE 93.8 IT 2.4 US 1.2
First	  Inventor	  country	  
(2010-­‐2012)
Second	  Inventor	  country	  
(2010-­‐2012)
Third	  Inventor	  country	  
(2010-­‐2012)
Notes:  To facilitate comparisons between companies the length of bars is calculated column wise. 
Patent families are fractional counted in case of multiple inventors and/or multiple applicants.
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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This chapter discusses the R&D and economic trends of 
companies based in Members States of the EU. This specific 
analysis is based on an extended sample of companies 
representing the top 1000 R&D investors in the EU, i.e. the 
608 EU companies included in the world top 2500 sample 
and 392 additional companies based in the EU.  The main 
questions addressed are firstly about the 2014 changes in 
R&D and economic indicators for companies based in the 
top 10 Member States by level of R&D investment. Secondly, 
the long-term trends of company results, such as the 
rate of growth of R&D and net sales and profitability for 
companies based in the top three Member States of the EU 
are examined.
The final section presents the results of an exercise aiming 
to improve the coverage of R&D investing companies in the 
EU and particularly in currently under-represented Member 
States.
Key findings
• Companies based in Germany, the top R&D investor, 
continued to increase R&D in 2014, at 6.3%, well above 
the EU average (3.3%). Companies based in the UK and 
France showed a modest increase of R&D (1.0% and 0.5% 
respectively). 
• Apart from the three top Member States, among the group 
of 10 EU countries with most R&D companies, those based 
in Ireland showed the highest R&D increase (15.7%), 
most of it due to companies such as Allergan, Medtronic, 
Alkermes and Seagate Technology18. Other countries whose 
firms increased R&D above the EU average were Denmark 
(8.8%), Sweden (8.7%) and Spain (7.1%). Companies 
based in Finland decreased R&D by 15.7% (largely due to 
Nokia’s R&D contraction, -21.4%) and those based in The 
Netherlands kept the same level of R&D.  
18 Companies headquartered in Ireland but with main operational centers in the US.
• The analysis of long-term trends of R&D and economic 
performance for companies based in Germany, the UK and 
France show the effects of the financial crisis of 2008-
2009 and the subsequent recovery over 2010-2012, 
especially for the German companies. Thereafter, the 
three countries show uneven trends, in 2013, the recovery 
slowed down with companies from the three countries 
showing a fall in net sales and also R&D for companies 
based in France. Over the last period, companies based in 
Germany recovered both R&D and net sales while those 
based in France and the UK continued to show poor results, 
especially in terms of net sales. The latter is mostly due 
to the results of large companies in terms of sales but 
with relatively small R&D, e.g. oil companies (Total, Shell, 
ENI) due to the sharply falling oil price, miners due to 
falling commodity prices due to the slowdown in China and 
banks partly because of stricter regulatory requirements 
following the financial crisis.
• An exercise aimed to identify further R&D investing 
companies in the EU found a quite limited number of 
companies. This is due mainly to data availability, i.e. R&D 
figures need to be reported in companies’ annual reports 
and audited accounts in order to apply the Scoreboard 
methodology. A different approach could be followed, for 
example, based on ad-hoc surveys or questionnaires to 
give an indication of companies having so far unrecorded 
R&D (though this would not give data of the quality 
required for the Scoreboard). A long term solution needs 
all countries to require compulsory disclosure of R&D in 
company reports.   
6 Extended sample of R&D 
investors in the EU
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6.1  Overview of the EU 1000 
companies  
The composition of the sample of the EU 1000 companies 
across industrial sectors and countries is found in Annex 
3.  This sample, as well as the global 2500, shows a high 
concentration of companies by sector and country. The 12 
largest sectors in terms of R&D account for 68% of the 
companies. These sectors and the top 5 countries in terms 
of number of companies are shown in Table 6.1. The UK has 
the most companies in the high tech sectors like biopharma 
and ICT while Germany has the most in medium tech sectors 
like automotive and engineering.
 
Table 6.1 - Distribution of the EU 1000 companies across main sectors and countries. 
Top 12 industries by R&D 
(ICB 3d) 
R&D 2014 
(€m) # companies Top 5 countries by number of companies
Automobiles & Parts 44 861.7 47 DE (16) UK (10) FR (6) IT (5) AT (4)
Pharmaceuticals & 
Biotechnology
31 909.6 122 UK (36) FR (19) DE (13) DK (10) SE (9)
Technology Hardware & 
Equipment
15 168.4 50 UK (16) FR (7) NL (7) DE (6) SE (6)
Aerospace & Defence 9 949.0 25 UK (9) FR (7) DE (2) IT (2) BE (1)
Electronic & Electrical 
Equipment
9 167.1 68 UK (18) DE (14) FR (8) FI (5) NL (5)
Industrial Engineering 9 139.4 101 DE (37) UK (12) SE (10) IT (8) FI (7)
Banks 7 617.9 27 DE (5) UK (4) BE (2) DK (2) IE (2)
Software & Computer Services 7 206.0 112 UK (49) DE (20) FR (16) SE (8) FI (5)
Chemicals 5 235.3 42 DE (13) UK (11) BE (3) FI (3) SE (3)
Fixed Line Telecommunications 4 285.6 11 AT (1) BE (1) DK (1) FR (1) DE (1)
Health Care Equipment & 
Services
3 923.0 37 DE (11) UK (11) SE (4) FR (3) BE (2)
General Industrials 3 656.5 37 DE (12) UK (9) SE (5) LU (2) NL (2)
All 41 industries 174 962.0 1000 UK (268)
DE 
(214)
FR 
(116) SE (80) NL (50)
Note: figures displayed refer to the sample of the EU1000 companies. 
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD
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Trends in the sector distribution of the R&D investments 
in the EU 1000
This section focuses on the trends in the R&D investments 
of the EU top 1000 RD investors separated into two groups: 
the upper reaches of the ranking (top 500 companies) 
and the lower reaches (bottom 500). It gives an overview 
of the changes between 2010 and 2014 in six selected 
sectors including Automobiles & Parts, Electronic & Electrical 
Equipment, Industrial Engineering, Pharmaceuticals & 
Biotechnology, Software & Computer Services and Technology 
Hardware & Equipment. 
These six selected sectors invested in R&D respectively about 
€93.3m in 2010 and €117.5 m in 2014. The figures 6.1a and 
6.1b show the change in the distribution of the lower and 
upper reaches of the EU top RD investors for the six sectors. 
The figures show different sector distributions across the two 
subgroups:
• Both subgroups have invested more than one quarter 
of their R&D in the Pharmaceuticals and Biotechnology 
industries in both 2010 and 2014. The 2014 R&D 
investment in software is almost as large as that in 
biopharma for the bottom 500 but is the lowest of the six 
sectors for the top 500.
• The R&D investment of the EU top 500 in Automobiles 
& Parts represents more than 30% while this is less 
than 10% of the R&D investment of the EU bottom 500 
companies.
• In relative terms, the third most important sector in terms 
of R&D investment is Industrial Engineering for the lower 
reaches (about 20% over 2010-2014) and Technology 
Hardware and Equipment for the upper reaches (18% in 
2010 and 13% in 2014).
• The R&D intensities of the two subgroups are similar for 
the Pharmaceuticals industry (11% to 13%), the Electronic 
& Electrical Equipment industry (around 4.5%) and the 
Industrial Engineering sector shows the lowest R&D 
intensities (about 1% for the lower reaches and 3% for the 
upper reaches).
• The R&D intensities for both the Technology Hardware 
& Equipment and software sectors in the upper reaches 
(12% to 15%) are more than twice the values for the lower 
reaches (3% to 6%). 
Figure 6.1a - Sector distribution of R&D for the EU top 500 companies.
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Note: figures displayed refer to the sample of the EU1000 companies. Please note the different scale respect to the figure 6.1b. 
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD
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6.2 Trends of companies in the 
top 10 Member States of the EU
There are 898 companies based in the top 10 Member 
States accounting for 97.4 % of the total R&D of the 1000 
EU sample (see table 6.2). 
The overall performance of the EU group is largely driven 
by the performance of companies based in Germany, France 
and the UK, accounting for 68.1% of the total R&D and 
68.5% of total net sales (see Tables 6.2 and 6.3).  The next 
seven countries only add another 29% of the total R&D. The 
German companies are clearly the largest group by R&D and 
just larger than the UK group by sales; this reflects the very 
different sector mixes of the two countries.
The 214 German companies in the EU 1000 sample, 
accounting respectively for 36.4 % and 27.1 % of the total 
R&D and net sales, increased R&D by 6.3% and net sales by 
2.8%.  These results reflect to a large extent the performance 
of the German companies in the Automobiles & Parts sector 
(7.8% in R&D and 6.2% in net sales). This sector accounts 
for 52.2% of R&D and 31.3 % of net sales of the group of 
German companies.
The 116 companies based in France, accounting respectively 
for 16.3 % and 17.3% of the total R&D and net sales of the 
EU 1000 sample, increased slightly their R&D investment 
(0.5%) and decreased net sales (-1.4%). The largest R&D 
investing sectors of the French sample showed mixed results, 
Pharmaceuticals & Biotechnology slightly decreased R&D 
(-0.3%) and increased net sales (2.2%) whereas Automobiles 
& Parts significantly increased R&D (8.2%) with net sales 
rising modestly by 0.8%.  
The 268 companies from the UK, accounting for 15.5 % and 
24.1 % of the total R&D and net sales of the EU 1000 sample, 
slightly increased R&D (1.0%) and for the second consecutive 
year reduced net sales (-5.0%) due to the large oil & gas, 
mining and banking companies which have very large sales 
but modest R&D. The largest R&D investing sectors of the 
UK sample presented contrasting figures, Pharmaceuticals 
& Biotechnology (2.3% in R&D and -4.1% in net sales) while 
Automobiles & Parts significantly increased R&D (7.6%) and 
modestly net sales (1.6%). 
Apart from the group of the three top countries, among 
the group of largest EU countries, those whose companies 
increased R&D above the EU average were Ireland (15.7%), 
Denmark (8.8%), Sweden (8.7%) and Spain (3.6%). 
Companies based in Finland significantly decreased R&D 
(-15.7%), mostly due to Nokia, accounting for two thirds 
of the total R&D by Finnish companies, showing a strong 
reduction of R&D (-21.3%). The companies based in the 
Netherlands for the second consecutive year did not increase 
Figure 6.1b - Sector distribution of R&D for the EU bottom 500 companies.
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R&D.  In term of net sales, many countries showed negative 
results, the poorest figures in net sales were for companies 
based in Finland (-11.8%) and Spain (-6.0%). 
It is important to remember that in many countries, the 
aggregate country indicators depend to a large extent on 
the figures of a very few firms. This is due, either to the 
country’s small number of companies in the Scoreboard or to 
the concentration of R&D in a few large firms. For example:
• Ericsson and Volvo accounting respectively for 40% and 
20% of the total R&D by the Swedish companies largely 
determined the overall R&D of their group (8.7%). Ericsson 
increased R&D by 17.3% and Volvo decreased it by 4.4%. 
• The Automobiles & Parts sector accounts for 52.2% of the 
R&D of companies based in Germany. Three companies 
in this sector, accounting for 37.5% of the German 
companies’ R&D, contributed a large part of that country’s 
R&D growth: Volkswagen (11.7%), Daimler (5.0%) and 
Robert Bosch (8.4%).
• The sharp R&D decrease of Alstom (-59.5%) affected 
strongly the R&D growth of the Industrial Engineering 
sector in the group of French companies.
• The relocation of Medtronic’s headquarter to Ireland from 
the US substantially increased that country’s R&D (since 
Medtronic is now Ireland’s largest R&D investor).  Allergan 
with main operational centre in the US but headquartered in 
Ireland increased R&D by 76%, mainly due to acquisitions 
- that boosted the Irish R&D growth rate.
Table 6.2 - R&D trends of companies based in the top 10 EU Member States.
Country No. of companies R&D Share within EU (%)
R&D one year 
growth (%)
Net Sales one year 
growth (%)
Germany 214 36.3 6.3 2.8
France 116 16.3 0.5 -1.4
UK 268 15.5 1 -5.0
The Netherlands 50 9.8 0 2.7
Sweden 80 5.5 8.7 5.3
Ireland 25 3.7 15.7 7.6
Italy 47 3.2 7.1 -2.2
Spain 22 2.6 3.6 -6.0
Finland 43 2.3 -15.7 -11.8
Denmark 33 2.3 8.8 2.0
Total EU 1000 100 3.3 -0.9
Note: figures displayed refer to the sample of the EU1000 companies. 
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD
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show a recovery of both R&D and net sales. Profitability 
was lower than that of the French and UK companies over 
the whole period. Sales recovered over the last year.
• Companies based in France showed a recovery in R&D 
and net sales in 2010-2011, however, over the period 
2012-2013 they presented an important decline in both 
net sales and R&D growth. In the last period they start 
recovering R&D and net sales but the growth rate for both 
was still negative. The average profitability of the French 
companies shows a decreasing trend in the period 2010-
2013 that has stabilised over 2013-2014.
• Companies based in the UK showed a strong recovery 
of R&D and net sales in 2010-2011 that was broken up 
in 2012. In 2012-2013 their R&D investment resumed 
to grow at significant pace but with a level of net sales 
practically unchanged. In 2014, the R&D level remained 
practically unchanged but with a significant decrease of 
net sales with falling oil and metals prices being a major 
factor. The average profitability of the UK companies is the 
highest of the three countries over the whole period but 
shows a decreasing trend in the period 2010-2012 that 
has stabilised over 2012 to 2014 in the range 9%-10%.  
Tab 6.3 -  R&D and Net Sales growth in 2014 on the top 12 industrial sectors for German, French and UK companies.
Sector EU 1000 R&D (€bn.)
Germany-214 France-116 UK-268
1-year change 
(%)
1-year change 
(%)
1-year change 
(%)
R&D      Sales R&D      Sales R&D      Sales
Automobiles & Parts 44.9 7.8 6.2 8.2 0.8 7.6 1.6
Pharmaceuticals & Biotechnology 31.9 7.3 3.0 -0.3 2.2 2.3 -4.1
Technology Hardware & Equipment 15.2 9.3 11.0 -4.4 -4.7 4.8 4.9
Aerospace & Defence 9.9 12.0 5.0 5.7 5.4 11.5 -6.4
Electronic & Electrical Equipment 9.2 -2.4 -3.9 9.9 4.4 9.3 3.2
Industrial Engineering 9.1 12.7 3.2 -49.0 -0.9 4.2 -3.7
Banks 7.6 33.0 -0.4 6.0 -1.3 -7.8 -7.6
Software & Computer Services 7.2 1.9 2.5 -5.2 12.7 12.1 7.1
Chemicals 5.2 3.1 1.0 11.2 0.0 10.0 -7.5
Fixed Line Telecommunications 4.3 -9.7 4.2 -6.2 -3.7 -4.3 -1.7
Health Care Equipment & Services 3.9 6.1 9.2 11.7 11.9 18.5 8.7
General Industrials 3.7 1.1 0.6 12.7 2.3 -2.3 -7.3
Top 12 industries 152.1 6.7 3.8 -0.1 1.3 3.0 -4.6
Rest of 28 22.8 0.6 0.9 2.5 -2.9 -5.5 -5.1
All 40 industries 175.0 6.3 2.8 0.5 -1.4 1.0 -5.0
Note: figures displayed refer to the sample of the EU1000 companies. 
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD
6.3  Long-term performance of 
companies based in the 3 top 
EU Member States
The annual growth rates of R&D investment and net sales 
and profitability of companies based in Germany, France and 
the UK is provided respectively in figures 6.2, 6.3 and 6.4 
for the period 2006-2014. These figures are based on our 
history database comprising R&D and economic indicators 
over the whole 2006-2014 period from the EU 1000 
dataset, including 152 companies from Germany, 82 from 
France and 160 from the UK. 
The trends observed in these figures show the behaviour 
of these companies including the effects of the crisis that 
began in 2008. The following points are observed:   
• Companies based in Germany showed a good performance 
over the period 2010-2012, recovering the levels of growth 
prior to the crisis, especially in terms of R&D. In the last 
period, they continued to increase R&D at a slower pace 
while maintaining a stable level of profitability but showing 
a decline in net sales. In the last period they continued to 
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Figure 6.2 - One-year R&D investment and net sales growth and profitability by the German companies.
Note:   growth rates for the three variables have been computed on 152 out of the 214 German companies for which data are available for the entire 
period 2007-2014.
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD
Figure 6.3 - One-year R&D investment and net sales growth and profitability by the French companies.
Note:  growth rates for the three variables have been computed on 82 out of the 116 French companies for which data are available for the entire 
period 2007-2014.
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD
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6.4 R&D intensity trends for 
companies based in selected 
Member States
 
In 2014, for the third consecutive year, the average R&D 
intensity of the EU-1000 companies increased because of 
the higher increase of R&D investments compared to that of 
net sales, 3.2% vs. -0.6% (see Figure 6.5). 
Figure 6.4 - One-year R&D investment and net sales growth and profitability by the UK companies.
Note:  growth rates for the three variables have been computed on 160 out of the 268 UK companies for which data are available for the entire period 
2007-2014.
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD
It is important to remember that a few large but low R&D 
intensity sectors have a big effect on some country average 
R&D intensities. One example is large Oil & Gas Producers, 
Mining companies and Banks for the UK. In 2014, these 
sectors contributed over 50% of the UK’s Scoreboard 
company sales, so if these three sectors had been left out, 
the average R&D intensity of UK companies would have 
increased from 1.7% to 2.9%.
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Figure 6.5 - Trends in R&D intensities for EU Scoreboard companies in selected Member States.
Note:  R&D intensity defined as R&D over Net Sales 
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD
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6.5 Further R&D companies in 
the EU
As explained in other sections of the report, industrial R&D is 
highly concentrated by country and by industry. In this year’s 
edition, the ranking of the top 1000 R&D investors in the EU 
includes companies from 21 member states. However, most 
of the companies are concentrated in a few countries, e.g. 
the top 3 countries account for 60 % of the companies.  
In addition, the methodological approach only takes into 
account parent companies in order to avoid double counting. 
For these reasons, many countries present very few 
companies and 7 EU countries show no company at all in the 
2015 Scoreboard. 
This section presents the results of an exercise aimed 
to increase the coverage of R&D investing companies in 
12 member states with zero or a very small number of 
companies in the Scoreboard (Slovenia, Greece, Poland, 
Czech Republic, Hungary, Slovakia, Croatia, Romania, Cyprus, 
Estonia, Latvia and Lithuania). 
This analysis followed a complementary approach, looking 
straightforwardly country by country for companies that 
report R&D figures, independently of the level of the 
investment and the type of company.  Apart from available 
commercial databases, various data sources have been 
applied including country-specific reports and Internet 
research.
The results of this exercise show 81 companies reporting 
R&D figures according to the Frascati methodology. The 
main data for these companies are summarised in Table 6.4. 
The full list of companies and related economic and R&D 
data are presented in Annex 4. Note that only 12 of the 81 
companies have sufficient R&D to warrant inclusion in the 
Scoreboard EU 1000 sample.
Concluding remarks
The number of companies, based in the selected countries, 
providing R&D figures complying with the Frascati definition 
is very limited. The main reasons are the following:
• Annual reports for a considerable number of companies 
are not always available in some countries.
• Many companies do not yet comply with international 
accounting standards, in particular regarding R&D figures 
that are often missing or generally stated as a percentage 
of turnover.
• In many cases, it is not possible to separate the company’s 
R&D effort from other funding sources such as state aids.
• Some countries have subsidiaries of foreign companies 
that do not file their own accounts or do not publish their 
own R&D figures.
• A general conclusion of this exercise is that the 
identification of further R&D companies in the selected 
countries should follow a different approach, for example 
supported by country relevant stakeholders and by means 
of ad-hoc surveys. However, these methods are unlikely 
to produce R&D data of the quality required for inclusion 
in the main Scoreboard. The longer term solution is for 
all EU countries to require all companies of significant 
size to publish annual reports and properly disclose R&D 
investment in those annual reports.
Table 6.4 - Further R&D investing companies in the EU.
Country number of companies Main industries Total R&D 2014 (€m)
Czech Republic 6 Automobiles, Banks, Iron & Steel 439.4
Slovenia 11 Pharmaceuticals, Auto Parts, Building Materials & Fixtures 114.5
Hungary 3 Pharmaceuticals, Banks 52.8
Poland 12 Mobile Telecom, Banks, Software, Chemicals 38.5
Slovakia 7 Tyres, General Industrials, Pharmaceuticals 27.4
Romania 8 Banks, Aerospace,  Oil & Gas 26.7
Greece 10 Telecom equip, construction, Containers & Packaging 18.4
Cyprus 3 Electricity, Industrials, Telecom 14
Croatia 8 Oil Equipment, Services & Distribution,  Food & Beverage 7.9
Estonia 5 Banks, Electricity 7.5
Latvia 6 Pharmaceuticals, Electrical Components & Equip. 5.8
Lithuania 2 Retailers, Oil& Gas 0.31
Total 81  753.21
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD
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Investment in research and innovation is at the core of the 
EU policy agenda. The Europe 2020 growth strategy includes 
the Innovation Union flagship initiative19 with a 3 % headline 
target for intensity of research and development (R&D)20. 
R&D investment from the private sector plays also a key 
role for other relevant Europe 2020 initiatives such as the 
Industrial Policy21, Digital Agenda and New Skills for New 
Jobs flagship initiatives. 
The Industrial Research and Innovation Monitoring and 
Analysis (IRIMA) project22 supports policymakers in these 
initiatives and monitors progress towards the 3 % headline 
target. The Scoreboard, as part of the IRIMA project, aims to 
improve the understanding of trends in R&D investment by 
the private sector and the factors affecting it.  
The annual publication of the Scoreboard is intended to raise 
awareness of the importance of R&D for businesses and to 
encourage firms to disclose information about their R&D 
investments and other intangible assets.
The data for the Scoreboard are taken from companies’ 
publicly available audited accounts. As in more than 99% 
of cases these accounts do not include information on the 
place where R&D is actually performed, the company’s 
whole R&D investment in the Scoreboard is attributed to the 
country in which it has its registered office23. This should be 
borne in mind when interpreting the Scoreboard’s country 
classifications and analyses. 
19 The Innovation Union flagship initiative aims to strengthen knowledge and 
innovation as drivers of future growth by refocusing R&D and innovation policies for 
the main challenges society faces.
20 This target refers to the EU’s overall (public and private) R&D investment 
approaching 3 % of gross domestic product (see: http://ec.europa.eu/europe2020/pdf/
targets_en.pdf).
21 The Industrial Policy for the Globalisation Era flagship initiative aims to improve 
the business environment, notably for small and medium-sized enterprises, and 
support the development of a strong and sustainable industrial foundation for global 
competition.
22 See:  http://iri.jrc.ec.europa.eu/home /. The activity is undertaken jointly by the 
Directorate General for Research (DG RTD A; see: http://ec.europa.eu/research/index.
cfm?lg=en) and the Joint Research Centre, Institute for Prospective Technological 
Studies (JRC-IPTS; see: https://ec.europa.eu/jrc/en/science-area/innovation-and-
growth). 
23 The registered office is the company address notified to the official company 
registry. It is normally the place where a company’s books are kept.
The Scoreboard’s approach is, therefore, fundamentally 
different from that of statistical offices or the OECD 
when preparing Business Enterprise Expenditure on R&D 
(BERD) data, which are specific to a given territory24 and 
give no information on which companies are performing 
the R&D and, indeed, are only based on returns from the 
larger companies (the smaller ones being estimated via a 
survey methodology). The Scoreboard data are primarily of 
interest to those concerned with benchmarking company 
commitments and performance (e.g. companies, investors 
and policymakers), while BERD data are primarily used by 
economists, governments and international organisations 
interested in the R&D being performed in territorial units 
defined by political boundaries. The two approaches are 
therefore complementary. The methodological approach of 
the Scoreboard, its scope and limitations are further detailed 
in Annex 2 below.  
Scope and target audience
The Scoreboard is a benchmarking tool which provides 
reliable up-to-date information on R&D investment and 
other economic and financial data, with a unique EU-focus. 
The 2500 companies listed in this year’s Scoreboard account 
for more than 90%25 of worldwide business enterprise 
expenditure on R&D (BERD). Furthermore, the dataset is 
extended to cover the top 1000 R&D investing companies 
in the EU. 
The data in the Scoreboard,  published since 2004, allow 
long-term trend analyses, for instance, to examine links 
between R&D and business performance.
24 The Scoreboard refers to all R&D financed by a company from its own funds, 
regardless of where the R&D is performed. BERD refers to all R&D activities performed 
by businesses within a particular sector and territory, regardless of the location of 
the business’s headquarters, and regardless of the sources of finance. The sources 
of data also differ: the Scoreboard collects data from audited financial accounts and 
reports whereas BERD typically takes a stratified sample, covering all large companies 
and a representative sample of smaller companies. Additional differences concern the 
definition of R&D intensity (BERD uses the percentage of R&D in value added, while 
the Scoreboard considers the R&D/Sales ratio) and the sectoral classification (BERD 
uses NACE (the European statistical classification of economic sectors), while the 
Scoreboard uses the ICB (the International Classification Benchmark).
25 According to latest Eurostat statistics. However BERD and Scoreboard figures are 
not directly comparable.
Annex 1 - Background information
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The Scoreboard is aimed at three main audiences. 
• Companies can use the Scoreboard to benchmark 
their R&D investments and so find where they stand in 
the EU and in the global industrial R&D landscape. This 
information could be of value in shaping business or R&D 
strategy. 
• Investors and financial analysts can use the Scoreboard 
to assess investment opportunities and risks.
• Policy-makers, government and business 
organisations can use R&D investment information as 
an input to policy formulation or other R&D-related actions 
such as the structure of R&D tax credit schemes. 
Furthermore, the Scoreboard dataset has been made freely 
accessible so as to encourage further economic and financial 
analyses and research by any interested parties.
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The data for the 2015 EU Industrial R&D Scoreboard 
(the Scoreboard) have been collected from companies’ 
annual reports and accounts by Bureau van Dijk Electronic 
Publishing GmbH (BvD). The source documents, annual 
reports & accounts, are public domain documents and so the 
Scoreboard is capable of independent replication. In order 
to ensure consistency with our previous Scoreboards, BvD 
data for the years prior to 2012 have been checked with the 
corresponding data of the previous Scoreboards adjusted for 
the corresponding exchange rates of the annual reports.
 
Main characteristics of the data
The data correspond to companies’ latest published 
accounts, intended to be their 2014 fiscal year accounts, 
although due to different accounting practices throughout 
the world, they also include accounts ending on a range of 
dates between late 2013 and mid-2015.  Furthermore, the 
accounts of some companies are publicly available more 
promptly than others. Therefore, the current set represents a 
heterogeneous set of timed data.
In order to maximise completeness and avoid double 
counting, the consolidated group accounts of the ultimate 
parent company are used. Companies which are subsidiaries 
of any other company are not listed separately. Where 
consolidated group accounts of the ultimate parent company 
are not available, subsidiaries are included.
In case of a demerger, the full history of the continuing entity 
is included. The history of the demerged company can only 
go back as far as the date of the demerger to avoid double 
counting of figures.
In case of an acquisition or merger, pro forma figures for 
the year of acquisition are used along with pro-forma 
comparative figures if available. 
The R&D investment included in the Scoreboard is the cash 
investment which is funded by the companies themselves. 
It excludes R&D undertaken under contract for customers 
such as governments or other companies. It also excludes 
the companies’ share of any associated company or joint 
venture R&D investment when disclosed. Where part or all 
of R&D costs have been capitalised, the additions to the 
appropriate intangible assets are included to calculate the 
cash investment and any amortisation eliminated.
Companies are allocated to the country of their registered 
office. In some cases this is different from the operational 
or R&D headquarters. This means that the results are 
independent of the actual location of the R&D activity. 
Companies are in industry sectors according to the NACE 
Rev. 226 and the ICB (Industry Classification Benchmark).
Limitations
The Scoreboard relies on disclosure of R&D investment 
in published annual reports and accounts. Therefore, 
companies which do not disclose figures for R&D investment 
or which disclose only figures which are not material enough 
are not included in the Scoreboard. Due to different national 
accounting standards and disclosure practice, companies of 
some countries are less likely than others to disclose R&D 
investment consistently. 
In some countries, R&D costs are very often integrated with 
other operational costs and can therefore not be identified 
separately. For example, companies from many Southern 
European countries or the new Member States are under-
represented in the Scoreboard. On the other side, UK 
companies are over-represented in the Scoreboard since the 
UK requires all companies above a certain minimum size to 
report R&D investment.
For listed companies, country representation will improve 
with IFRS adoption.
The R&D investment disclosed in some companies’ accounts 
follows the US practice of including engineering costs 
relating to product improvement. Where these engineering 
costs have been disclosed separately, they have been 
excluded from the Scoreboard. However, the incidence of 
non-disclosure is uncertain and the impact of this practice is 
26 NACE is the acronyme for “Nomenclature statistique des activités économiques 
dans la Communauté européenne”.
Annex 2 - Methodological notes
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a possible overstatement of some overseas R&D investment 
figures in comparison with the EU. 
Where R&D income can be clearly identified as a result of 
customer contracts it is deducted from the R&D expense 
stated in the annual report, so that the R&D investment 
included in the Scoreboard excludes R&D undertaken under 
contract for customers such as governments or other 
companies. However, disclosure practice differs and R&D 
income from customer contracts cannot always be clearly 
identified.  This means a possible overstatement of some 
R&D investment figures in the Scoreboard for companies 
with directly R&D related income where this is not disclosed 
in the annual report.
In implementing the definition of R&D, companies exhibit 
variability arising from a number of sources: i) different 
interpretations of the R&D definition. Some companies view 
a process as an R&D process while other companies may 
view the same process as an engineering or other process; ii) 
different companies’ information systems for measuring the 
costs associated with R&D processes; iii) different countries’ 
fiscal treatment of costs.
Interpretation
There are some fundamental aspects of the Scoreboard 
which affect their interpretation.
The focus of the Scoreboard on R&D investment as reported 
in group accounts means that the results can be independent 
of the location of the R&D activity. The Scoreboard indicates 
the level of R&D funded by companies, not all of which is 
carried out in the country in which the company is registered. 
This enables inputs such as R&D and Capex investment to be 
related to outputs such as Sales, Profits, productivity ratios 
and market capitalisation. 
The data used for the Scoreboard are different from data 
provided by statistical offices, e.g. BERD data. The Scoreboard 
refers to all R&D financed by a particular company from 
its own funds, regardless of where that R&D activity is 
performed. BERD refers to all R&D activities performed by 
businesses within a particular sector and territory, which are 
often just a part of a company, regardless of the location of 
the business’s headquarters, and regardless of the sources 
of finance. 
Further, the Scoreboard collects all data from audited financial 
accounts and reports. BERD typically takes a stratified 
sample, covering all large companies and a representative 
sample of smaller companies. Additional differences concern 
the definition of R&D intensity (BERD uses the percentage of 
value added, while the Scoreboard measures it as the R&D/
Sales ratio) and the sectoral classification they use (BERD 
follows NACE, the European statistical classification of 
economic sectors, while the Scoreboard classifies companies’ 
economic activities according to the ICB classification).
Sudden changes in R&D figures may arise because of a 
change in company accounting standards. For example, 
the first time adoption of IFRS27, may lead to information 
discontinuities due to the different treatment of R&D, i.e. 
R&D capitalisation criteria are stricter and, where the criteria 
are met, the amounts must be capitalised. 
For many highly diversified companies, the R&D investment 
disclosed in their accounts relates only to part of their 
activities, whereas sales and profits are in respect of all their 
activities. Unless such groups disclose their R&D investment 
additional to the other information in segmental analyses, it 
is not possible to relate the R&D more closely to the results 
of the individual activities which give rise to it. The impact 
of this is that some statistics for these groups, e.g. R&D as 
a percentage of sales, are possibly underestimated and so 
comparisons with non-diversified groups are limited.
At the aggregate level, the growth statistics reflect the growth 
of the set of companies in the current year set. Companies 
which may have existed in the base year but which are 
not represented in the current year set are not part of the 
Scoreboard (a company may continue to be represented in 
the current year set if it has been acquired by or merged 
with another). 
For companies outside the Euro area, all currency amounts 
have been translated at the Euro exchange rates ruling at 
31 December 2014 as shown in Table A2.1. The exchange 
rate conversion also applies to the historical data. The 
result is that over time the Scoreboard reflects the domestic 
currency results of the companies rather than economic 
estimates of current purchasing parity results. The original 
domestic currency data can be derived simply by reversing 
the translations at the rates above. Users can then apply 
their own preferred current purchasing parity transformation 
models. 
 
27 Since 2005, the European Union requires all listed companies in the EU to prepare 
their consolidated financial statements according to IFRS (International Financial 
Reporting Standards, see: http://www.iasb.org/). 
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Table A2.1 -  Euro exchange rates applied to the 2015 Scoreboard data for companies based in different 
currency areas (as of 31 Dec 2014).
Country As of 31 Dec 2013 As of 31 Dec 2014
Australia $ 1.56 $ 1.48
Brazil 3.25 Brazilian real 3.22 Brazilian real
Canada $ 1.47 $ 1.41
China 8.42 Renminbi 7.43 Renminbi
Czech Republic 27.43 Koruna 27.72 Koruna
Denmark 7.46 Danish Kronor 7.43 Danish Kronor
Hungary 297.62 Forint 314.46 Forint
India 85.40 Indian Rupee 76.86 Indian Rupee
Israel 4.79 Shekel 4.72 Shekel
Japan 145.14  Yen 146.41  Yen
Mexico 18.03 Mexican Peso 17.87 Mexican Peso
Norway 8.38 Norwegian Kronor 9.02 Norwegian Kronor
Poland 4.15 Zloty 4.26 Zloty
Russia 45.15 Rouble 68.31 Rouble
South Korea 1449.28 Won 1333.33 Won
Sweden 8.86 Swedish Kronor 9.39 Swedish Kronor
Switzerland 1.23 Swiss Franc 1.20 Swiss Franc
Turkey 2.95 Turkish lira 2.82 Turkish lira
UK £ 0.84 £ 0.78
USA $ 1.38 $ 1.21
Taiwan $ 41.42 $ 40.02
Source: The 2015 EU Industrial R&D Investment Scoreboard, European Commission, JRC/DG RTD.
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Glossary of definitions
1. Research and Development (R&D) investment in 
the Scoreboard is the cash investment funded by the 
companies themselves. It excludes R&D undertaken 
under contract for customers such as governments 
or other companies. It also excludes the companies’ 
share of any associated company or joint venture R&D 
investment. Being that disclosed in the annual report and 
accounts, it is subject to the accounting definitions of 
R&D. For example, a definition is set out in International 
Accounting Standard (IAS) 38 “Intangible assets” and 
is based on the OECD “Frascati” manual. Research is 
defined as original and planned investigation undertaken 
with the prospect of gaining new scientific or technical 
knowledge and understanding. Expenditure on research 
is recognised as an expense when it is incurred. 
Development is the application of research findings or 
other knowledge to a plan or design for the production 
of new or substantially improved materials, devices, 
products, processes, systems or services before the start 
of commercial production or use. Development costs are 
capitalised when they meet certain criteria and when 
it can be demonstrated that the asset will generate 
probable future economic benefits. Where part or all of 
R&D costs have been capitalised, the additions to the 
appropriate intangible assets are included to calculate 
the cash investment and any amortisation eliminated.
2. Net sales follow the usual accounting definition of 
sales, excluding sales taxes and shares of sales of joint 
ventures & associates. For banks, sales are defined as 
the “Total (operating) income” plus any insurance income. 
For insurance companies, sales are defined as “Gross 
premiums written” plus any banking income.
3. R&D intensity is the ratio between R&D investment and 
net sales of a given company or group of companies. 
At the aggregate level, R&D intensity is calculated only 
by those companies for which data exist for both R&D 
and net sales in the specified year. The calculation of 
R&D intensity in the Scoreboard is different from than in 
official statistics, e.g. BERD, where R&D intensity is based 
on value added instead of net sales. 
4. Operating profit is calculated as profit (or loss) before 
taxation, plus net interest cost (or minus net interest 
income) minus government grants, less gains (or plus 
losses) arising from the sale/disposal of businesses or 
fixed assets.
5. One-year growth is simple growth over the previous 
year, expressed as a percentage: 1 yr growth = 100*((C/
B)-1); where C = current year amount, and B = previous 
year amount. 1yr growth is calculated only if data exist 
for both the current and previous year. At the aggregate 
level, 1yr growth is calculated only by aggregating those 
companies for which data exist for both the current and 
previous year.
6. Three-year growth is the compound annual growth 
over the previous three years, expressed as a percentage: 
3 yr growth = 100*(((C/B)^(1/t))-1); where C = current 
year amount, B = base year amount (where base year = 
current year - 3), and t = number of time periods (= 3). 
3yr growth is calculated only if data exist for the current 
and base years. At the aggregate level, 3yr growth is 
calculated only by aggregating those companies for 
which data exist for the current and base years.
7. Capital expenditure (Capex) is expenditure used by 
a company to acquire or upgrade physical assets such 
as equipment, property, industrial buildings. In accounts 
capital expenditure is added to an asset account (i.e. 
capitalised), thus increasing the asset’s base. It is 
disclosed in accounts as additions to tangible fixed 
assets.
8. Number of employees is the total consolidated average 
employees or year-end employees if average not stated.
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The 2015 Scoreboard comprises two data samples:
• The world’s top 2500 companies that invested more than 
€18.0m in R&D in 2014.
• The top 1000 R&D investing companies based in the EU 
with R&D investment exceeding €5.5m.
 For each company the following information is available: 
• Company identification (name, country of registration and 
sector of declared activity according to ICB classifications).
• R&D investment 
• Net Sales 
• Capital expenditure 
• Operating profit or loss 
• Total number of employees
• Main company indicators (R&D intensity, Capex intensity, 
Profitability)
• Growth rates of main indicators over one year and three 
years.
Annex 5 - Access to the full dataset
The following links provide access to the two Scoreboard 
data samples containing the main economic and financial 
indicators and main statistics over the past four years.
R&D ranking of world top 2500 companies: http://iri.
jrc.ec.europa.eu/documents/10180/d7f67bce-288d-4c71-
9d5d-67058c912511
R&D ranking of EU top 1000 companies:
http://iri.jrc.ec.europa.eu/documents/10180/c0035c57-
3ba5-4dbc-85f1-1a669f50f9fb
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significant lower pace (2.2%). 
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